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Current methods to diagnose and treat cancer often involve expensive, time-
consuming equipment and materials that may lead to unwanted side effects and may not 
even increase a patient’s chance of survival. Thus, for a while now, a large part of the 
research community has focused on developing improved methods to detect, diagnose, 
and treat cancer on the molecular scale. One of the most recently discovered methods of 
cancer therapy is targeted therapy. These targeted therapies have potential to provide a 
patient with a form of personalized medicine because these therapies are biological 
molecules that specifically target other molecules involved with a cancer’s growth. 
Past trials using these therapeutic molecules, however, have led to controversial 
results, where certain patients responded better than others to the therapy for unknown 
reasons. Elucidating the reason behind these mixed results can be accomplished using 
metal nanoparticle technologies which could provide a bright signal to monitor the path 
that these therapeutic molecules take in vivo as well as enhance the molecule’s efficacy. 
Literature has shown that presenting targeting molecules in a dense manner to their target 
 viii
will increase these molecules’ binding affinity. This concept has been explored here to 
increase binding affinity of therapeutic molecules by attaching these molecules in a dense 
manner on the surface of gold nanoparticles, and correlating this increased affinity with 
therapeutic efficacy. Additionally, gold nanoparticles provide an easy surface for 
molecules to be functionalized on and have shown to be effective imaging, x-ray, and 
photothermal therapy agents. A major roadblock to using these gold nanoparticles 
clinically is their non-degradability and thus potential to cause long-term negative side 
effects in vivo. A platform for developing biodegradable gold nanoparticles is also 
explored here to take advantage of the gold nanoparticles’ excellent imaging and drug 
delivery capabilities while still allowing them to be used safely in the long term. 
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Chapter 1: Introduction 
1.1  BACKGROUND: CURRENT LIMITATIONS IN DIAGNOSING AND TREATING CANCER 
Cancer is a disease where cells divide uncontrollably. According to the National 
Cancer Institute’s Surveillance, Epidemiology, and End Results (SEER) program, the 
expected number of deaths from cancer in the U.S. in 2012 is 577, 190, meaning 1,500 
people are expected to die from cancer each day. The most common cancers are lung, 
bronchus, prostate, breast, and colorectal, and the lifetime probability of having cancer is 
quite high: 45% for men and 38% for women1. 
Even though cancer is a complex disease, there are basically six essential changes 
that normal cells undergo to become malignant cancer cells: self-sufficiency, 
unresponsiveness to antigrowth signals, evasion of programmed cell death, endless 
potential to replicate, tissue invasion, and metastasis2. Research into the mechanism 
behind this uncontrollable growth has revealed a complex circuit of molecules inside and 
outside the cell that play a large, interconnected role in cancer cell growth. For example, 
one important class of molecules involved in cancer growth is cell surface receptors that 
interact with growth stimulatory signals. These receptors can become deregulated and 
overexpressed, allowing the receptor to be hypersensitive to growth signals and trigger 
proliferation when, in normal cases, the receptor would not. One receptor that is 
overexpressed in multiple types of tumors including stomach, brain, breast, and lung is 
the epidermal growth factor receptor (EGFR). Ligand-independent signaling has been 
shown to occur with EGFR because a truncated version of the cytoplasmic domain of 
EGFR can fire constitutively2.  
In a person, these molecular abnormalities can manifest themselves as symptoms 
such as thickening of tissue, discomfort in eating, and unusual discharge. If a patient 
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exhibits symptoms of cancer, a physician will order tests that involve collecting blood 
and urine to ensure certain vital organs are functioning normally and to detect any tumor 
markers. These tests, however, are not sure signs of a presence of a disease, so medical 
imaging procedures are a crucial part of an accurate diagnosis3. 
Typical imaging procedures used to detect cancer are x-ray, computed 
tomography (CT) scans, radionuclide scans, positron emission tomography (PET) scans, 
magnetic resonance imaging (MRI), and ultrasound3. Though x-ray, CT, radionuclide, 
and PET scans can achieve high contrast for certain anatomical features, they are all 
limited by the dose of radiation or radioactive material that can be given to a patient. 
Additionally, these techniques are quite expensive to run. MRI provides a safer from of 
whole body imaging, but MRI is the most expensive imaging technique being used and 
lacks sensitivity. Ultrasound imaging is a safe and cost-effective method of imaging, but 
this technique lacks resolution, which is necessary for identifying early abnormalities 
such as neoplastic changes4. Technologies to enhance contrast in images can 
simultaneously improve resolution and decrease the required dose of excitation energy, 
allowing for safer and higher resolution imaging procedures to be available. 
Oftentimes, to diagnose a patient, a physician will also collect a biopsy, which is a 
small sample of tissue, and send the sample to a pathologist who will stain the sample for 
different cellular markers and image the sample with a microscope3. This 
histopathological investigation is the gold standard for determining if cancer is present. 
This method, however, can be subjective because the result is based on an interpretation 
of the pathologist. Thus, more objective techniques are being explored to give more 
functional and quantitative information of the tissue sample. 
If a physician determines the patient does indeed have cancer, standard methods 
of treatment include surgery, radiation therapy, and/or chemotherapy. Newer methods of 
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treatment include biological therapy and stem cell transplantation. Often, treatments 
damage healthy cells as well as cancer cells, and thus negative side effects ranging from 
rashes to death have been observed3. Recently, many research groups have worked to 
improve these existing therapeutic methods as well as improve current diagnostic 
methods to increase sensitivity, be less invasive, and yield results more quickly. 
1.2 TARGETED THERAPY FOR TREATING CANCER ON THE MOLECULAR SCALE 
Targeted therapies are substances that block tumors from growing by interfering 
with molecules that are critical for tumors to grow. Many of these therapies are small-
molecule inhibitors or monoclonal antibodies5. Small-molecule inhibitors are typically 
identified in drug screens, while monoclonal antibodies are generated by immunizing a 
mouse with a target molecule and hybridizing the mouse’s spleen cells with myeloma 
cells to produce a hybridoma cell line that will produce the monoclonal antibodies. 
Typically, for targeting intracellularly, small molecule inhibitors are used because they 
can diffuse into a cell, but for targeting cell surface receptors, larger, monoclonal 
antibodies are used. Certain types of monoclonal antibodies such as anti-EGFR 
antibodies, however, can enter cells by being actively transported into the cell after 
binding to a cell surface receptor indicating great potential for some antibodies to act as 
intracellular delivery agents. 
Recent promising targets of cancer therapy include: oncogenes such as cMYC6, 
inflammatory markers surrounding a cancer7, various proteins such as nuclear factor 
kappa-light-chain-enhancer of activated B cells (NF-kappa B)8, signal transducer and 
activator of transcription (STAT) proteins9, vascular endothelial growth factor receptors 
(VEGFRs)10, and epidermal growth factor receptors (EGFRs)11.  
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In particular, EGFR has been extensively studied as a target because this receptor 
has been shown to be very important in the progression of multiple types of cancer. 
Patients with alterations in these receptors tend to have a more aggressive disease and 
thus worse clinical outcome12. The family of EGFRs consists of four types: 
EGFR/ERBB1, ERBB2, ERBB3, and ERBB4. All types have a ligand-binding domain 
on the surface of the cells and a cytoplasmic domain for binding tyrosine kinases. Upon 
binding of EGF ligands, EGFR will form homo- and heterodimers, and the cytoplasmic 
kinase domain of EGFR will be activated. There are two main types of EGFR drugs: 
small-molecule tyrosine-kinase inhibitors (TKIs) that block the tyrosine kinase from 
activating the cytoplasmic domain of the receptor by binding to the kinase’s adenosine 
triphosphate (ATP)-binding site, and surface receptor-binding antibodies that block 
ligands from binding to the receptor extracellularly. 
One monoclonal antibody targeting EGFR that is currently used in the clinic and 
in clinical trials is Cetuximab. Cetuximab has been shown to strongly inhibit cancer cell 
growth in EGFR-overexpressing cells and in mice tumor xenografts13. This antibody was 
approved by the FDA in 2003 for colorectal cancer and in 2006 for head and neck 
squamous cell carcinoma. Recent clinical trials have yielded mixed results, where some 
trials showed that Cetuximab improved the odds of response and reduced disease 
progression14, while other trials have shown no difference in overall survival15.  
Targeted therapy induces cell death directly by apoptosis or indirectly by 
activating immune cells. Studies described here have also shown that targeted therapies 
assembled on a platform of nanoparticles can also induce another type of cell death, 
autophagy. Furthermore, understanding the pathways activated by our therapeutic 
molecules will allow us to design and tailor our therapy to a wide variety of individual 
patient’s particular health needs. 
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Though we will not discuss here, other emerging forms of targeted therapy 
include cancer vaccines and gene therapy. One concern of targeted therapies is their 
ability to become ineffective over time as the cancer develops resistance. In particular, 
resistance to anti-EGFR drugs has been observed, leading many to suggest targeted 
therapies like Cetixumab be used in combination with other drugs such as HER2/neu 
targets to increase therapeutic efficacy16.  
1.3 NANOPARTICLES FOR IMAGING AND TREATING CANCER 
1.3.1 Overview 
Nanoparticles hold great potential for offering improved methods to treat and 
image cancer. Along with the fact that traditional drugs for cancer are non-specific, 
another large problem with systemically administered drugs is that often, the cancer 
develops resistance to these drugs17. Resistance means that a tumor is not decreasing in 
size or has relapsed after initially decreasing18. Resistance can come in two forms: non-
cellular based and cellular based17. Non-cellular based resistance arises from poor 
vasculature, acidic microenvironments, and high interstitial pressure. Cellular based 
resistances arise from altered enzyme activity, altered apoptosis and transport 
mechanisms, and increased multi-drug resistance (MDR) efflux systems18-19. 
Nanoparticles offer a way to overcome these drug resistances by protecting drugs during 
their transport as well as decreasing their toxicity toward normal cells. Additionally, 
nanoparticles have shown an ability to evade MDR, and some speculate this is because a 
protein that is often involved in MDR, P-glycoprotein (Pgp), only activates efflux of 
drugs when the drugs are in the plasma membrane, and not if they are in the cytoplasm or 
in lysosomes (Figure 1.1).  
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Figure 1.1 (A) Free doxorubicin is small enough to diffuse into a cancer cell, but is 
effluxed by a multi-drug resistance (MDR) protein, Pgp. (B) Doxorubicin 
encapsulated in nanospheres bind to the cell membrane and release 
doxorubicin, creating a concentration gradient that could saturate Pgp and 
overcome MDR17. 
Nanoparticles are submicrometer colloidal systems that can act as delivery 
vehicles for drugs. These nanoparticles can accumulate in a tumor via passive diffusion 
across a highly permeable tumor vasculature20 or by active targeting21. Additionally, 
retention of nanoparticles in the tumor can occur from poor clearance by lymphatics of 
neoplastic tissue. To detect a tumor and its boundaries, many nanoparticles have been 
used to target specific cancer markers and provide qualitative and quantitative analyses of 
tumor location and spread. Common nanoparticles used for treating and imaging cancer 
are organic, quantum dots, magnetic, carbon, and gold nanoparticles. 
1.3.2 Organic nanoparticles 
1.3.2.1 Polymer-drug conjugates 
In the 1980’s, the first nanoparticles were used to deliver drugs in clinical trials, 
and a decade later, these nanoparticle-drug conjugates became commercially available22. 
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One of the earliest reports of using nanoparticles to treat cancer was in 1979 with drugs 
adsorbed onto a polymer nanoparticle, polyalkylcyanoacrylate23. Polymers are the most 
commonly researched material to develop nanoparticle carriers. Polymer-drug conjugates 
(6-15nm) have been shown to target various types of tumors and blood vessels, and as of 
2006, had 12 products being evaluated in clinical trials24. Though a wide range of drugs 
and polymers have been used in research, only four drugs (doxorubicin, amptothecin, 
paclitaxel, and palatinate) and four polymers (N-(2-hydroxylpropyl)methacrylamide 
(HPMA) copolymer, poly-L-glutamic acid, poly(ethylene glycol) (PEG), and dextran) 
have been used to develop polymer-drug conjugates22.  
1.3.2.2 Liposomes 
Researchers have shown that liposomes of a size of 200nm can effectively 
extravasate from leaky vasculature to a nearby tumor25. In the past few years, liposomes 
(85-100nm) have been extensively studied in Phase I-III clinical trials, and are used to 
treat solid tumors. Liposomes are spherical, closed structures formed by multiple lipid 
bilayers. These lipid based carriers are biocompatible, biodegradable, and their surface 
can be easily modified. These carriers, however, have been shown to rapidly clear from 
the body via the reticuloendothelial system17, 26 and are characterized by a burst release of 
drug. 
1.3.2.3 Polymeric nanoparticles 
Polymeric nanoparticles can be made of synthetic polymers like polylactic acid 
and poly(lactic-co-glycolic acid), or of natural polymers like chitosan and collagen. 
These polymeric nanoparticles are in the size range of 50-200nm, and are being studied 
in Phase I-III clinical trials for treating a variety of cancers27. 
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1.3.2.4 Dendrimers 
Dendrimers are synthetic macromolecules that have a branched structure, are 
biocompatible, and have high water solubility22. Additionally, targeting molecules, 
imaging agents, and drugs can be easily conjugated to these dendrimers. Challenges to 
their use in the clinic include the fact that they are rapidly cleared from the body owing to 
their small size, and are more expensive to make compared to other types of 
nanoparticles. 
1.3.3 Quantum dots 
Nanoparticles can also serve as contrast agents. Traditionally, clinically used 
optical imaging methods involve fluorophores as contrast agents. Fluorescent proteins 
and organic dyes, however, are neither as bright nor as stable as metal nanoparticles or 
quantum dots (Figure 1.2).  
 
 
Figure 1.2 Organic dyes undergo more photobleaching than quantum dots. Top row: 
Nuclei of 3T3 cells were labeled with quantum dot QD 630-streptavidin 
(red) and microtubules were simultaneously labeled with AlexFluor 488 
(green). Bottom row: Microtubules were labeled with QD 630-streptavidin 
(red) and nuclei were labeled were labeled with AlexaFluor 488 (green). 
Scale bar is 10µm28. 
Quantum dots are particles that are quantum confined, surrounded by a stable 
polymer shell29. These quantum dots have unique optical and electronic properties with 
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molar extinction coefficients about 10-100 times larger than traditional organic dyes30, 
size-tunable fluorescence emission in near infrared wavelengths29, and a broad excitation 
spectrum that allows for multiplexing by exciting a mixed population of quantum dots, 
while detecting emission wavelengths that are far from their excitation31. Quantum dots 
were first synthesized in the early 1980’s32 and since then, have been used in diagnostic 
devices33. One of the earliest uses in vivo was imaging and quantifying cancer 
biomarkers on the surface of pancreatic cancer cells34, image tumors and lymph nodes in 
mice29, 35, and as photo-therapy agents36. Concerns over the quantum dots’ toxicity had 
initially plagued their ability to be seen as a clinical diagnostic and treatment tool, but 
more recently, researchers have shown they are nontoxic if protected by a stable 
coating29, 30b, 37  
1.3.4 Magnetic nanoparticles 
Currently, magnetic resonance imaging (MRI) is the preferred method of cross-
sectional imaging in the brain, spine, and muscoskeletal system38. Magnetic nanoparticles 
have proven to be useful as dual functioning MRI contrast agents and therapeutic 
hyperthermia agents. The first reported use of magnetic nanoparticles in vivo was in the 
10th century and involved magnetite grains that were given to a patient who had 
swallowed rust, to speed up the excretion of the poisonous rust38. 
Recently, magnetic nanoparticles have been used to deliver a large payload to 
specific areas in the body and provide strong contrast in MRI images using an externally 
applied magnet targeted to the site of interest. Nd-Fe-B capsules were delivered to the 
brain with an accuracy of 2mm38, and dextran-coated iron oxide nanoparticles showed 
strong potential as MRI contrast agents39. MRI is based on a nuclear magnetic resonance 
(NMR) signal of protons, after being excited by a strong static magnetic field  (clinically, 
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up to 2T) and a transverse radiofrequency-field (5-100MHz). The excited protons relax 
back to equilibrium as the net magnetization vector tries to realign with the longitudinal 
axis of the magnetic field40. There are two types of relaxation processes: T1-recovery, 
which is longitudinal relaxation, and T2-decay, which is transverse relaxation. Different 
types of tissue have different T1 and T2 values. Fluids typically have a long T2 and are 
associated with diseases38. Initial forays into gaining contrast in MRI came from the 
difference between deoxy- and oxygenated hemoglobin, but this difference was very 
small, so researchers turned to using exogenous contrast agents. The first exogenous 
agents were gadolinium (Gd) ions, which are high spin paramagnetic ions38. To protect 
tissue from the Gd ions’ toxicity, a chelator DTPA was incorporated into the contrast 
agent. From there, superparamagnetic materials were explored and showed higher 
magnetic moment than the paramagnetic particles. These superparamagnetic contrast 
agents yielded T2-relaxation effects, which resulted in a signal reduction on T2-weighted 
images38. Most T2 agents are made up of Fe3O4 or Fe2O3. When these Fe3O4 or Fe2O3 
nanoparticles are in the presence of a magnetic field, they induce a local field 
inhomogeneity that causes nearby protons to dephase. This dephasing results in 
transverse relaxation, and the total relaxation time T2* is given by Equation (1). 
 
ଵ
்ଶ∗ ൌ ቀ
ଵ
்ଶቁ ൅ ߛܤݏ (1) 
 
where ߛܤݏ represents the relaxation by field inhomogeneities and is the susceptibility 
effect41.  
Magnetic nanoparticles used for hyperthermia of cancer would require 
nanoparticles to be concentrated around or inside a tumor. These nanoparticles would 
then absorb energy from an external alternating magnetic field and heat its 
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surroundings38. There are two types of hyperthermia: mild hyperthermia which heats 
tissue between 41-46 degrees C to stimulate an immune response, and thermoablation, 
which heats tissue up to 56 degrees C, which leads to tumor destruction via necrosis42. 
Studies have shown that certain parameters must be met for hyperthermia to be usable for 
patients. The product of the amplitude and the frequency of the magnetic field must be 
lower than 4.85x108 Am-1s-1 for one hour, and the frequency must be higher than 50kHz 
to avoid electrically stimulating neuromuscular junctions but lower than 10MHz to 
achieve good penetration depth38. Upon excitation by an AC magnetic field, the magnetic 
moments of nanoparticles rotate and then relax to equilibrium, termed Neel relaxation. In 
2003, a successful human trial using Fe3O4 nanoparticles modified with aminosilane 
groups to induce hyperthermia was demonstrated in a patient with chondroscarcoma, 
which is a cancer comprised of cells that produce cartilage38. Additionally, iron oxide 
nanoparticles have also been used in diagnostic devices to detect circulating tumor cells 
using immunomagnetic properties combined with a microfluidic device for high-
throughput monitoring of cancer ex vivo43. 
1.3.5 Carbon nanoparticles 
Carbon nanostructures have shown strong potential as medical contrast agents44. 
They have shown to have higher relaxivity values compared to conventional MRI 
contrast agents composed of Gd-(III), are biocompatible, and can cross cell membranes44. 
Limitations of these particles, however, include the fact that these particles have 
demonstrated aggregation in vivo and are quickly taken up by the reticuloendothelial 
system 45. Recent developments have improved the stability of these nanoparticles and 
have allowed for renal clearance within one hour of injection46. 
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1.3.6 Gold nanoparticles 
Since the 1970’s, metal nanoparticles have been used to immunolabel biological 
molecules for electron microscopy47. More recently, gold nanoparticles have been used in 
cellular and medical imaging48. Compared to other nanoparticles, gold nanoparticles 
serve as a flexible platform for tuning a variety of parameters such as size, shape, 
composition, and structure, which lead to various optical properties49. Chapter 2 will 
discuss further the chemical and optical properties of gold nanoparticles and their recent 
uses as biomedical delivery, contrast, and therapeutic agents. 
1.4 DISSERTATION SUMMARY 
This dissertation builds on the past few decades of research that indicate strong 
potential for metal nanoparticles to be used as diagnostic and therapeutic agents of 
cancer. Here, we look at specific parameters that are of utmost clinical importance such 
as the nanoparticles’ ability to enhance therapeutic efficacy of currently used drugs, and 
the particles’ ability to be efficiently cleared by the body to avoid potential long term side 
effects.  
Chapter 2 examines the properties of gold nanoparticles that are critical for their 
in vivo use, and their recent uses as delivery, imaging, and therapeutic agents in cells and 
animals. 
Chapter 3 looks at the therapeutic efficacy and activated paths of therapeutic 
antibodies conjugated to gold nanoparticles on lung cancer cells. These antibodies are the 
mouse analog of a clinically used targeted antibody-drug, Cetuximab. 
Chapter 4 provides a method for developing biodegradable plasmonic 
nanoparticles and shows both in vitro degradation and in vivo clearance of biodegradable 
gold nanoclusters. 
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Chapter 5 summarizes the use of gold nanoparticles as clinically useful diagnostic 
and therapeutic agents, and the outlook of using these nanoparticles in the clinic
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Chapter 2: Requirements of Nanoparticles for In Vivo Use: Properties 
and Applications in Molecular Medicine 
Metal nanoparticles, especially plasmonic nanoparticles such as gold 
nanoparticles, have shown a strong potential for a variety of biomedical applications, 
ranging from ex vivo sensing to in vivo therapy. To be used in vivo, nanoparticles must 
have certain properties: be biocompatible, characterizable, functionalizable, soluble or 
colloidal, have low rate of aggregation, exhibit uptake into target cells over normal cells, 
allow for monitoring over time, and have long circulating life22. In this chapter, examples 
of nanoparticles, with emphasis on gold nanoparticles, and the properties that allow them 
to meet these requirements are given. Additionally, recent uses of these nanoparticles in 
diagnosis and therapy are highlighted. 
2.1 PROPERTIES OF GOLD NANOPARTICLES 
2.1.1 Synthesis 
2.1.1.1 Spheres 
An initial synthesis of gold nanoparticles was developed in 1951 by Turkevich50 
and involves reducing gold ions to nanoparticles using citrate51, where the citrate also 
stabilizes the already-formed nanoparticles. Stabilizers other than citrate can be used 
during synthesis of gold and will prevent aggregation via Coulombic repulsion or steric 
hindrance52. The size of the nanoparticles can be tuned simply by controlling the ratio of 
citrate to HAuCl453. This type of solution phase synthesis of metal nanoparticles allows 
for control over size, shape, composition, and structure of the particles and tends to yield 
an energetically favorable shape of a sphere52. 
A more recent method for synthesizing gold spheres was developed in 2000 using 
a seed-mediated growth to synthesize a more monodisperse solution for large diameter 
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(>20nm) spheres than the previously used Turkevich method. This synthesis involved 
growing the gold nanoparticles using initial gold seeds and NH2OH. 
Another commonly used procedure for synthesizing gold particles is the Brust-
Schiffrin method54. This method involves both an aqueous and an organic phase along 
with a phase-transfer agent tetractylammonium bromide to reduce AuCl4 anions with 
NaBH4 in the presence of alkanethiols, resulting in thiol-stabilized particles55. Since then, 
simpler, single-phase methods have been developed. 
2.1.1.2 Non-spherical particles 
Non-spherical particles such as rods can be made using established methods such 
as electrochemical ionization and reduction of gold56 or seed-mediated growth using gold 
spheres as seeds to grow rods in the presence of excess gold ions and surfactant 
cetyltrimethylammonium bromide (CTAB)57. Because CTAB is considered cytotoxic, 
other less cytotoxic surfactants have been explored such as liquid-chlorin photosensitizers 
from algae and choline hydroxide51. The aspect ratio of these rods can be easily changed 
by varying the concentration of silver ions49. These rods exhibit plasmon resonances in 
the near infrared region (NIR), which is optimal for medical optical-based imaging 
because common tissue chromophores have low absorption in the NIR wavelength range 
(Figure 2.1). 
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Figure 2.1 Optical properties of gold nanoparticles change with shape. (Top left) 
Photographs of solutions of 4 nm gold spheres (vial 0) followed by 
increasing aspect ratios (vials 1-5). (Top right) Absorbance spectra of 
solutions from vials 1-5. (Bottom) TEM of nanoparticles from vials 1-5. 
Scale bars are 100 nm in all TEM images58. 
Another type of metal nanoparticle that can be tuned to the NIR range is a 
core/shell nanostructure of silica/gold, termed nanoshells. The silica cores are 
functionalized with an amine-terminated silane that binds to small gold particles. 
Subsequent layers of gold are added by electroless plating59. A similar method has also 
been used to synthesize another NIR absorbing particle, the nanorice60. 
Another procedure for synthesizing NIR absorbing particles involves using 
ethylene glycol as a solvent and reducing agent at elevated temperatures. This procedure 
has been used to synthesize NIR absorbing nanoplates and nanocages61. 
2.1.2 Bioconjugation 
Gold nanoparticles capped with citrate can be easily replaced with other ligands62. 
A stable bond between thiol and gold was first observed in 199363. More recently, a 
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popular method of thiolating gold nanoparticles is performed using the Schiffrin-Brust 
synthesis as described in Chapter 2.1.1.154. Another popular method of conjugating to 
gold nanoparticles is through a “click” reaction, linking terminal alkyne and an azide64. A 
common method of functionalizing gold nanoparticles that have a terminal carboxylate 
group is to attach a molecule with an amino group on one end using EDC chemistry and a 
desired group on the other end65. Nanoparticles have also been conjugated to a versatile 
molecule, the dendrimer, using a solution containing a pre-organized number of internal 
ligands during synthesis, resulting in dendrimer encapsulated gold nanoparticles51, 66. 
Stable nanoparticle conjugates have been synthesized using PEG sorbitan fatty acid esters 
functionalized with lipoic acid, which contains a disulfide bond. These conjugates have 
been shown to be stable in environments of pH 1-1451, 66. Recently, directional 
conjugation of antibodies has been achieved by allowing the antigen-binding sites of the 
Fab portion of an antibody to be directed outward towards the target67 (Figure 2.2). This 
is accomplished by attaching a heterobifunctional linker to the Fc region of a 
glycosylated antibody, allowing the Fab portion of the antibody to be free to interact with 
a target. The linker consisted of an amide-bonded adipic hydrazide and an alkane ending 
in a dithiol group to attach to gold nanoparticles with near-covalent strength. 
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Figure 2.2 Schematic of directional conjugation of antibodies on gold nanoparticle 
surface67. 
2.1.3 Optical properties  
Optical properties of gold nanoparticles have been of interest since Faraday 
reported the first scientific article about them in 185751. Then in 1908, Mie used 
Maxwell’s equations to describe the extinction spectra of spherical particles of arbitrary 
size68. Because Mie’s theory assumes the spherical particles and surrounding media are 
homogenous52, there are some challenges when applying this theory to medical optics69. 
Complicating factors include non-spherical particles, the presence of a supporting 
substrate, a solvent layer on top of the particles, and particles that are so close together 
there is electromagnetic coupling of the particles69. 
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Since Mie’s time, numerical methods such as T-matrix formalism, discrete dipole 
approximation (DDA)70, and finite-difference time-domain simulations71 have been used 
to calculate the optical properties of nanoparticles for complex cases. Mie’s theory, 
however, is still widely used today because it is the only simple, exact solution to 
Maxwell’s equations that is relevant to particles52. 
When light irradiates a small metal sphere, the incoming oscillating electric field 
causes the sphere’s conduction electrons to oscillate coherently (Figure 2.3). 
 
 
Figure 2.3 Schematic of a displacement of an electron charge cloud relative to the 
nucleus of a metal sphere, resulting in a localized surface plasmon52. 
Subsequently, after these conduction electrons are displaced, the electrons are 
attracted back to the positively charged nucleus, resulting in an oscillation at a frequency 
that is governed by: the density of electrons, effective electron mass, and shape and size 
of the charge distribution. This collective oscillation of electrons is termed the dipole 
plasmon resonance of the particle69, which is the simplest type of local surface plasmon 
resonance (LSPR). Larger particles have higher multipoles, where a quadrupole term 
must be taken into account, as well as retardation effects52, 69. Very small nanoparticles 
<3 nm do not exhibit this plasmon resonance because at this small size, the gold is no 
longer a piece of metal with a conduction band, but is a molecule described by its 
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molecular orbitals51. The particle’s dipole plasmon frequency occurs because all the 
conduction bands oscillate in phase with each other and this leads to a buildup of 
polarization charge at the surface of the particle52, 69. There is also a homogenous buildup 
of charge inside the particle and this is manifested in strong scattering and an enhanced 
electric field at the surface of the particle52. The LSPR’s maximum intensity and spectral 
position varies with the size, shape, composition, and local environment of the 
nanoparticle72. 
The optical properties of noble metal nanoparticles are best described by a 
complex, wavelength-dependent dielectric constant ߳ given by Equation (2)52. 
߳ሺߣሻ ൌ ߳rሺߣሻ ൅ ݅߳iሺߣሻ	 (2) 
where ߳ ൌ ݉2 and ݉ ൌ ݊ ൅ ݅݇ is the complex refractive index given as a function of the 
refractive index, n, and the absorption coefficient, k. In the electrostatic dipole regime, 
the extinction of a spherical metal nanoparticle can be described by Equation (3). 
 
ܧሺߣሻ ∝ ఢiሺఢr + χఢmed)2 + ఢi2	  (3) 
where ߳med is the dielectric constant of the surrounding medium, ߣ is the excitation 
wavelength, χ is a form factor that is related to the aspect ratio (χൌ2 for a sphere, and 
increases with increasing aspect ratio), ߳i is the imaginary component of the dielectric 
function of the metal spheres, and ߳r is the real component. When the real component of 
the dielectric constant is much greater than the imaginary component, then a maximum 
extinction occurs when ߳r	ൌ‐2	*	߳med. At this maximum is where the LSPR occurs52. 
When the refractive index increases, there is a red shift in extinction spectrum 
because of a buildup of polarization charges on the dielectric side of the interface, which 
will weaken the total restoring force52. When we have larger particles beyond the 
Rayleigh approximation (diameter > 30nm), a red shift is also observed as well as a 
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broadening of the extinction spectrum. The red shift occurs because as the particle 
becomes larger, the conduction electrons do not all move in phase with each other and 
this causes a retardation effect which leads to a reduced depolarization field at the center 
of the particle73. Broadening of the spectrum is attributed to radiative losses, which could 
translate into a loss of sensitivity for biosensing applications74.  
For a NIR absorbing particle such as a nanorod, the plasmon resonance exhibits 
two peaks, and as the aspect ratio increases, so does the distance between the two 
conduction bands. Other NIR absorbing agents such as triangular nanoparticles also have 
multiple plasmon resonances, with very large field enhancements at their tips75. 
Typical sizes of gold nanoparticles that are used for biomedical applications are 
40-80 nm. Using Mie theory and discrete dipole approximation, extinction and scattering 
efficiencies were calculated for three common types of gold nanoparticles: spheres, rods, 
and nanoshells, along with some conventionally used absorbing dyes for comparison76. 
Results showed that, compared to conventional absorbing dyes, all gold nanoparticle 
types yielded orders of magnitude higher optical cross sections than absorbing and 
fluorescent dyes76. Gold particles of 40nm in size are often used as biological imaging 
agents. These 40nm spheres yielded an absorption cross section of 7.7x109 M-1cm-1 at 
528nm, which is five orders of magnitude greater than a clinically used NIR absorbing 
dye indocyanine green (ICG), 1.1x104 M-1cm-1 at 778nm. 80nm particles showed an 
equally high margin in scattering cross section (3.2x1010 M-1cm-1) over a commonly used 
fluorescent molecule, fluorescein (9.2x104 M-1cm-1 at 483nm with a quantum yield of 
~0.98)76. 
Using these calculations, for spheres, as diameter increased from 20 to 80 nm, so 
did the extinction and scattering contribution. Red shifting occurred slightly with 
increasing size. Nanoshells demonstrated advantages over spheres in that they exhibited 
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plasmon resonances in the NIR as well as had higher optical cross-sections. Their 
extinction was linearly dependent on their overall size, but independent of their core/shell 
radius. The scattering contribution increased as thickness of the shell increased, and red 
shifting occurred as the total size of the nanoshell increased or with a decrease in shell 
thickness. Concerning rods, as the effective size increased, so did the extinction and 
relative scattering contribution, but the absorption contribution remained dominant for all 
sizes of rods. Both extinction and scattering contribution were independent of the rod’s 
aspect ratio, but red shifting occurred with increasing effective radius or increasing aspect 
ratio. Ultimately, per micron, rods yielded an order of magnitude higher absorption and 
scattering than both spheres and rods. Thus, rods are strong candidates for optical 
imaging agents in vivo, however, their biocompatibility, stability under laser heating, and 
clearance in vivo still need to be fully characterized before they can be widely used as a 
systemic agent. 
2.1.4 Cytotoxicity 
There have been concerns about the cytotoxicity of gold nanoparticles at the 
concentration that they will typically be administered at, which is 1-100 nanoparticles per 
cell51. In general, reports have shown that gold nanoparticles show little toxicity51. 
Cationically functionalized aklythioloate-gold nanoparticles containing 
trimethylammonium ligand termini were used to translocate DNA across a cell 
membrane and were only toxic at concentrations that were two times higher than needed 
for maximal transfection. Control nanoparticles without cationic surface charge were 
non-toxic51. Another study showed that gold nanoparticles bound to a variety of ligands 
including biotin, cysteine, citrate, and glucose did not appear toxic to human leukemia 
cells (K562) up to a concentration of 250 mM, while HAuCl4 was highly toxic, killing 
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90% of cells77. Results of nanoshells in mice showed no complications78. Au-Cu-shells 
led to dose dependent cytotoxicity, with 67% viability at higher doses51. The CTAB layer 
on gold nanorods has been shown to be toxic79, but rods coated in layer-by-layer 
polyelectrolytes showed low toxicity80. Another ligand, PEGylated-biotin-PEG-
poly(caprolactone) conjugated to gold nanoparticles showed minimal toxicity on Caco2 
cells80. 
2.1.5 Biodistribution  
Blood and lymphatic vessels provide a route for nanoparticles to be delivered to 
specific sites in the body, but it is not clear how to manipulate this intricate path of 
vessels to target certain sites81. Even the most active compounds in vitro are useless if 
they do no circulate in the blood long enough to reach their target by avoiding the 
immune system and rapid excretion82. Different routes of administration have led to 
different biodistributions. Injections of nanoparticle-drug conjugates via subcutaneous, 
intramuscular, and topical routes have led to a higher retention of drug than free drug, but 
the conjugates were typically found in local lymph nodes83. The uptake of nanoparticles 
by phagocytes in vivo depends on the size, surface charge, and hydrophobicity of the 
particles84. The mononuclear phagocyte system, or the reticuloendothelial system, 
consists of bone marrow progenitors, blood monocytes, and tissue macrophages85. During 
the clearance process, first, circulating proteins called opsonins absorb onto foreign 
particles and then interact with certain receptors on monocytes and macrophages38. These 
opsonins include fibronectin, immunoglobulins, and complement proteins81. Different 
types of particles attract different types of opsonins, leading to different clearance rates 
for these different particles86.  
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After intravenous injection, typically, nanoparticles are rapidly cleared from the 
blood by the liver’s Kupffer cells and the spleen’s marginal zone and red pulp21. 
Nanoparticles larger than 200 nm clear faster than small nanoparticles21. Long-circulating 
particles are ideal for tumor accumulation because they predominantly escape the blood 
stream only when there are fenestrations such as in the sinus endothelium of the liver or 
when there is leaky vasculature such as is typically found surrounding a tumor21, 87. Liver 
fenestrations can be as large as 150 nm, while tumor capillary fenestrations can be as 
large as 300 nm81. Splenic filtration often occurs as well, with slits as large as 200-250 
nm21. Nanoparticles with long circulation times have been achieved using clodronate to 
impair macrophages in the liver88, but this strategy will be difficult to translate to the 
clinic because an essential defense system will be suppressed potentially for a couple of 
weeks38, 88a. 
Coating nanoparticles with amphiphilic chains has been observed to decrease 
phagocytosis of the nanoparticles in vivo, and lead to an increase in blood residence 
time89. Also, hydrophilic coatings of dextran, poloxamer (PEO-PPO-PEO) and PEG have 
been used to add stealth to the particles by suppressing macrophage recognition, leading 
to reduced adsorption and surface opsonization81. Poloxamine-908-coated spheres 
showed to increase the blood half-life of spheres up to 1-2 days90. PEG has shown to 
suppress protein adsorption at an optimal molecular weight of 2kD to 5kD21, 91. Recently, 
to increase stability of PEGylated nanoparticles in vivo, a short hydrophobic layer was 
conjugated to gold nanoparticles on one end and to PEG on the other end. The 
hydrophobic layer provides a shield to prevent proteins from slipping through the PEG 
layer and destabilizing the PEGylated particles. These novel conjugates have shown 
decreased uptake in macrophage cells compared to PEGylated nanoparticles without a 
 25
hydrophobic layer, indicating great potential for these conjugates to have increased 
stealth  in vivo92. 
The biological distribution of gold nanoparticles after intravenous administration 
showed that overall, nanoparticles between the sizes of 15-200 nm accumulated in the 
liver, spleen, and lungs. Distribution between other organs was size dependent. Both 15 
and 50 nm were found in the brain, while only a small amount of 200 nm particles was 
found in the brain, blood, stomach, and pancreas93. A similar study injecting gold 
nanoparticles into rats showed 10 nm particles were distributed between various organs 
while 50-250 nm particles ended up only in liver, spleen, and blood94. Typically, 
nanoparticles of 30-100 nm in size are optimal to prevent rapid clearance from blood by 
leakage into blood capillaries and macrophages95. Surface chemistry can also play a role 
in biodistribution. Bare hydrogel nanoparticles have shown to have an increased 
accumulation in the liver compared to the spleen, while PEGylated hydrogels showed a 
more even distribution between liver and spleen96. A hypothesis for this difference in 
distribution is that particles with longer circulation times have a higher chance of being 
exposed to the spleen and thus uptake by splenic phagocytes is more likely for PEGylated 
particles which have a longer circulation time than non-PEGylated particles97. 
Concerning very small gold nanoparticles, an intravenous injection of 1.4 and 1.8 nm 
particles showed that 1.4 nm could travel through the air/blood barrier in the lungs, but 
1.8 nm was trapped in the lungs98. 
Comparing lipoic acid and monothiol PEG, gold nanoparticle surfaces 
functionalized with lipoic acid were more stable, and comparing 20, 40, and 80 nm gold 
conjugated to 5kD PEGylated lipoic acid, 20 nm yielded the lowest uptake by the 
reticuloendothelial system and the highest uptake into a tumor99. Targeting agents can be 
conjugated to the nanoparticle surface to improve the stability of the nanoparticles and 
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increase affinity of the nanoparticles to a tumor100, as well as determine the nanoparticle’s 
path of internalization, whether through receptor-mediated endocytosis or lipid raft-
dependent macropinocytosis81. More recent results, however, showed that targeting 
agents may not always influence tumor accumulation as much as specific cell uptake 
after already arriving in the tumor vicinity via passive targeting101. Gold nanorods 
conjugated to ScFv antibodies did not show statistically different accumulation in a tumor 
compared to non-targeted nanorods, but histopathology revealed that targeted nanorods 
accumulated in tumor cells while non-targeted nanorods accumulated in extracellular 
matrix101b. 
2.2 GOLD NANOPARTICLES FOR BIOMEDICAL APPLICATIONS 
2.2.1 Sensing and imaging 
Besides the traditional application of using gold nanoparticles in immunostaining 
for TEM, gold nanoparticles have been used as contrast agents in a wide variety of 
detection and imaging methods such as biosensing technologies, magnetic resonance 
imaging (MRI), surface enhanced Raman scattering (SERS), and photoacoustic (PA) 
imaging. 
2.2.1.1 Biosensing 
For detecting molecules in solution, gold spheres, nanoshells102, nanorods58, and 
nanowires103 have been used to detect proteins104, viruses105, and nucleic acids106 at as 
low as femtomolar concentrations of target analyte. Gold nanoparticles have been 
extremely useful in biosensing techniques because of their plasmon coupling property. 
When the inter-particle space decreases, the color of the solution changes, and this color 
change can provide a quick visual detection of the presence of an analyte. In 1980, initial 
studies involving this plasmon coupling effect for sensing was performed by 
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Leuvering107, and more recently this method has been improved upon using hyper-
Raleigh scattering. In 1996, Mirkin was the first to use this colorimetric type of assay 
using gold nanoparticles to detect nucleic acids106 and he and his colleagues have since 
extended the technique to detect endonuclease activity in real time108. Gold nanoparticles 
have also been used in fluorescence detection assays. Though gold nanoparticles have 
low quantum yields, they fluoresce strongly under a high excitation light51. Gold 
nanoparticles have also been used as strong fluorescent quenchers, and have shown to 
quench fluorescent dyes by 50% when the dyes are only 25 nm away109. This quenching 
method has been used to detect large proteins that can act as a spacer between a 
fluorophore and a gold nanoparticle to inhibit quenching110. Gold nanoparticles have also 
served as nanoelectrodes for electrochemical sensing because the turnover rate of 
electrons transferred through gold nanoparticles is about seven times higher than through 
some catalytic enzymes such as glucose oxidase51. 
2.2.1.2 MRI 
For whole body imaging such as MRI, 2 nm gold particles have been used to 
deliver Gd chelates to a specific site in the body and showed a higher relaxivity (586 nM-
1s-1) than gold nanoparticle-free Gd chelates (3 nM-1s-1)111. Hybrid nanoparticles made up 
of gold coated iron oxide nanoparticles have also shown strong potential as dual optical 
and MRI contrast agents in T2 weighted imaging (Figure 2.4)112  . 
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Figure 2.4 MRI images of cell phantoms labeled with anti-EGFR hybrid core/shell iron 
oxide/gold nanoparticles. Left: Sections (a)-(d) are MDA-MB-468 cells 
treated with anti-EGFR hybrid nanoparticles from (a) highest concentration 
to (d) lowest concentration, and (f) is a positive control of cells labeled with 
the highest concentration of nanoparticles. Middle: T2 weighted image of 
the tubes in the left photo. Right: T1 weighted image of the tubes in the far 
left photo112b. 
 2.2.1.3 SERS 
Gold nanoparticles have also been extensively used for surface enhanced Raman 
scattering (SERS) techniques. When Raman active molecules are placed within 10 nm of 
a gold nanoparticle surface, an enhanced SERS signal 1014-1015 can occur, which could 
lead to single molecule detection51. This enhancement arises from an electronic coupling 
of the molecules with the gold nanoparticles and the nanoparticle’s plasmon resonance, 
which leads to an increase in the Raman signal to the fourth power of the local dielectric 
field51. SERS has been used to differentiate cancerous cells from non-cancerous cells 
using gold nanorods conjugated to anti-EGFR antibodies113, and to differentiate 
unhealthy acidic cells from healthy cells using nanoshells114. SERS has also extended to 
in vivo tests, detecting a tumor as small as 0.03 cm3 using gold nanoparticles conjugated 
to ScFv antibodies at a penetration depth of 1-2 cm (Figure 2.5)100. 
 29
 
 
Figure 2.5 SERS of ScFv antibody conjugated gold nanoparticles with Raman reporter, 
malachite green, injected via tail vein into nude mice bearing head-and-neck 
squamous cell carcinoma xenograft tumors. SERS spectra from tumor (red 
spectrum) and liver (blue spectrum) of (a) targeted particles and (b) non-
targeted particles were obtained 5 hrs after injection. (c) Photos of the 
anatomical location of the tumor (left) and the liver (right) are pointed 
out100.  
2.2.1.4 Photoacoustic imaging 
Recently, gold nanoparticles have also been used in photoacoustic (PA) imaging, 
which is a technique that images tissue absorbers using a pulsed light excitation and 
ultrasound detection. Developments in PA imaging combined with gold nanoparticles 
have shown high sensitivity, molecular specificity, and penetration depth in imaging 
diseases like cancer (Figure 2.6)115 and cardiovascular disease116 as well as important 
structures like blood117 and sentinel lymph nodes118 that can provide information about 
the early onset of these diseases. Even more recently, along with diagnosis, photoacoustic 
imaging has been used to detect migration of stem cells for therapeutic purposes119. 
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Figure 2.6 Ultrasound (a) and photoacoustic (b-f) images of gelatin phantoms 
implanted in a mouse ex vivo illuminated at wavelengths 532, 680, 740, 
800, and 860 nm, respectively. In (a), the red circle is human epithelial 
carcinoma cells (A431) treated with anti-EGFR gold nanoparticles, the 
white circle is cells only, the green circle is cells mixed with non-specific 
PEGylated nanoparticles, and the blue circle is control NIR dye115. 
2.2.1.5 Other modalities 
Other optical imaging modalities that have been used in conjunction with gold 
nanoparticles to target and image cancer cells include mulitphoton microscopy120, optical 
coherence microscopy121, and third-harmonic microscopy49.  
2.2.2 Clinical diagnostics 
Since the 1950’s, gold nanoparticles have been used as radioactive labels in vivo. 
Gold nanoparticles have shown advantages over conventional organic dyes and quantum 
dots because of reduced toxicity, resistance to photobleaching, unique spectroscopic 
properties, and surface enhanced effects51.  
One of the most promising uses of gold nanoparticles in clinical diagnoses is 
enhancing signal from enzyme-linked immunosorbent assays (ELISAs). These types of 
tests include immunochromatographic test strips, where both the primary and secondary 
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antibodies are conjugated to gold nanoparticles. This technique has been demonstrated in 
detecting gonadotropin hormone at 1 pg/mL122. Nanoshells have also been used as 
contrast agents in ELISA-based tests to determine IgG content in whole blood102. Gold 
nanoparticles have also been used to detect nucleic acids of clinical relevance such as 
single nucleotide polymorphisms (SNPs) and mutations that have been known to lead to 
diseases such as cancer123.  
Cancer diagnostics have been extensively studied using gold nanoparticles as 
sensing and imaging agents. Large gold nanoparticles strongly scatter light and when 
they are immunotargeted to cancer markers such as epidermal growth factor receptor 
(EGFR), they can be illuminated with a simple laser pointer48c or with white light124 
(Figure 2.7).  
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Figure 2.7 Laser scanning confocal reflectance images with 647 nm excitation 
wavelength of (a) precancerous and (b) normal fresh cervical tissue ex vivo 
labeled with ant-EGFR gold nanoparticle conjugates48c. 
Other diseases that gold nanoparticles have been used to detect in conjunction 
with emerging technologies include Alzheimer’s disease125 and HIV126. 
2.2.3 Therapy 
2.2.3.1 Photothermal therapy 
Laser hyperthermia, or photothermal therapy, uses optical heat to ablate a tumor 
to avoid the non-specific side effects that traditional methods of therapy suffer from51. 
Absorbing agents such as indocyanine green (ICG) and iron oxide have been used for 
photothermal therapy of cancer, but these agents provide only small cross sections and 
thus a large concentration of agents is needed to be effective. Thus, there has been a large 
interest in using gold nanoparticles to alleviate these problems because gold nanoparticles 
are considered non-toxic and have high absorption cross sections51. After gold 
nanoparticles are irradiated, they convert light to heat extremely quickly, in about 1 ps127. 
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Smaller gold nanoparticles 10-30 nm in size are of optimal size to be delivered to a tumor 
and when aggregated on a cell’s surface, can be irradiated with NIR wavelengths of light, 
resulting in bubble formation112b, 128. SK-Br-3 cancer cells have been photothermally 
destroyed both in vitro and in vivo using PEGylated nanoshells. The shells cause a local 
increase in temperature to 37.4 ± 6.6°C at a depth of 2.5 mm for 5 min, using a laser 
dosage that was 10-25 times less than needed for ICG. More recently, nanoshells have 
been used to ablate 98% of a prostate tumor in vivo using an 810 nm laser with a 200 nm 
laser fiber at 4Wcm-2 129. Larson et al. also showed significant photothermal damage 
using anti-EGFR antibodies conjugated to hybrid gold shell iron oxide core nanoparticles 
on EGFR-overexpressing cancer cells using a single 400 mJcm-2 pulse at 700 nm 
wavelength, with no effect on cells that were exposed to non-specific PEGylated hybrid 
nanoparticles (Figure 2.8)112b. 
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Figure 2.8 Photothermal therapy of MDA-MB-468 breast cancer cells using anti-EGFR 
hybrid gold nanoparticles. Fluorescence images of cells treated with (a) anti-
EGFR hybrid nanoparticles and (b) PEGylated hybrid nanoparticles after 
one 7 ns 400mJcm-2 laser pulse at 700 nm. Green fluorescence is from 
calcein AM staining that indicates cell survival. (c) Dark-field reflectance 
images of cells treated with anti-EGFR hybrid nanoparticles after one 7 ns, 
400mJcm-2 laser pulse at 700 nm. (d) Fluorescence image of cells treated 
with PEGylated hybrid nanoparticles after six hundred 7 ns, 400mJcm-2 
pulses at 700 nm. Scale bar is approximately 100 µm in the fluorescence 
images and 50 µm in the dark-field image112b. 
A NIR absorbing hollow nanoparticle comprised of both silver and gold has 
shown selective damage to lung cancer cells A549 with a laser power that was 
significantly reduced compared to the power needed for rods130.  
2.2.3.2 Targeted delivery for therapy and gene therapy 
Nanoparticles have also acted purely as delivery vehicles. Nanoparticles carrying 
a photodynamic therapy agent, phtalocyanine, generated singlet oxygen upon excitation 
with light, inducing apoptosis and necrosis in tumors131. Gold nanoparticles have also 
been used to deliver DNA, small interfering RNA (siRNA), and drugs through surface 
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functionalization62d. Additionally, concentrating drugs on the surface of nanoparticles can 
lead to a decrease in non-specific systemic toxicity. A cytokine that can induce apoptosis, 
tumor necrosis factor (TNF-α), decorated on the surface of 33 nm PEGylated particles 
maximized tumor damage while minimizing systemic exposure to TNF-α132. Gold 
nanoparticles have also shown to decrease angiogenesis by binding to heparin-binding 
growth factors and inhibiting the phosphorylation of proteins that are critical for 
angiogenesis133. This inhibition has also been used to image and treat arthritis by 
reducing the presence of macrophages and monitoring the process with photoacoustic 
imaging134. Gold nanorods have shown to effectively treat antifibrotic disorders by 
modulating cell-mediated matrix remodeling. Three-dimensional phantoms of collagen 
and cardiac fibroblasts were treated with polyelectrolyte-coated gold nanorods and a 
reduced contraction and expression of mRNA-encoding actin and collagen type I were 
observed135. 
Potential gene therapy applications have also been reported using gold 
nanoparticles to deliver plasmid DNA via gold-polyethylenimine (PEI) conjugates136 and 
negatively charged oligonucleotides137. 
2.2.3.3 Hyperthermia 
Radiofrequencies (RF), frequencies of 10 kHz – 900 MHz, have been used for 
healing purposes during the last century, but only since the 1990’s have these frequencies 
been used to treat tumors in the liver51. This technique is currently limited by the need to 
implant heating needles at the tumor and the inability to monitor the heat generation. 
Additionally, this therapy has suffered from damage to nearby healthy liver as well as a 
relatively high observation of recurrence51. Recently, gold nanoparticles have been used 
with RF heating to induce cancer death in a rat using 35 mW of power138.  
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Hyperthermia has been demonstrated using not only magnetic nanoparticles, but 
also with nanoshells that accumulated in a tumor and disrupted the perivasculature139. 
2.3 MULTIMODAL NANOPARTICLES 
The future of personalized medicine relies heavily on the future of molecular 
imaging. Though there are a handful of molecular imaging techniques, no single modality 
will provide all the information a researcher or physician requires140. Current molecular 
imaging methods used clinically have limitations: optical imaging is difficult to quantify 
as you delve deep into tissue, magnetic resonance imaging (MRI) has good resolution but 
low sensitivity, and positron emission tomography (PET) has poor resolution but high 
sensitivity. Multimodal probes offer the ability to combine the advantages of multiple 
imaging modalities to enhance the visualization of biological processes and collect data 
more reliably140. 
Molecular imaging is the ability to see within the body and understand biological 
processes on the molecular scale140. This should allow us to visualize fundamental 
alterations that molecules undergo in a disease as opposed to visualizing only the 
endpoint, thus giving us a better understanding of the disease and allowing us to detect 
the disease earlier. Ideally, agents would allow us to non-invasively monitor processes 
over time140. Molecular imaging has been achieved using inorganic nanoparticles made 
up of iron oxide, quantum dots, gold, and silica. Because of these nanoparticles’ small 
sizes, they can interact with biological molecules, have readily tunable properties, and 
potential to be multifunctional. 
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2.3.1 MRI/Optical 
2.3.1.1 Paramagnetic agents 
Commercially available MRI contrast agents include Magnevist and Dotarem, 
which are gadolinium (Gd) chelates. Gd-nanoparticle conjugates with dual MRI/optical 
contrast have been developed using Gd-lipid-rhodamine nanoparticles, and these particles 
were found to evenly distribute throughout breast cancer cells141. Gd chelates-
nanoparticles have also been developed using a dendrimer PAMAM142 and quantum 
dots143. A Gd-DOTA-silica nanoparticle yielded a high 15000mM-1s-1 relaxivity with a 
1.4T MRI, and these particles showed promise for in vivo translation because they 
efficiently cleared through the bladder143. These silica nanoparticles have also been doped 
with fluorophores or metals such as ruthenium to create dual fluorescence/MRI imaging 
agents140, 144. Another triple modality nanoparticle was developed for imaging with 
photoacoustic imaging, Raman spectroscopy, and MRI. The nanoparticles consisted of a 
gold core for photoacoustic imaging, a Raman active layer for Raman spectroscopy, and 
a gadolinium layer for MRI145. 
Along with conventional fluorophores, quantum dots have also been used as 
optical imaging agents in multimodal imaging. Quantum dots have relatively high 
absorption cross sections in the Vis and NIR range of 10-15 cm2, which is an order of 
magnitude higher than NIR fluorophores and thus have shown to be strong photothermal 
microscopy and photoacoustic agents. Care must be taken, however, to limit toxicity of 
the quantum dots, whose cores could potentially disintegrate after being irradiated146. 
CdSe/ZnS core/shell quantum dots conjugated to a lipid-based Gd nanoparticle showed 
relaxivities of 12mM-1s-1, which is three times higher than the clinically used Gd-
DTPA147. 
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Silica nanoparticles doped with quantum dots and paramagnetic lipids showed a 
quantum yield of 35% and an MRI relaxivity of 14.4 mM-1s-1148. Silica-quantum dot 
nanoparticles have also been doped with manganese to yield T1 relaxivity values of 
12mM-1s-1 and a quantum yield of 8.1% in water with NIR two-photon microscopy, with 
limited toxicity when given to cells. Though this is a promising dual NIR imaging/MRI 
agent, challenges with this agent are that the synthesis of the agent is complicated and 
there is a need for post-processing the optical data149. 
2.3.1.2 Superparamagnetic agents 
Along with gadolinium, iron oxide nanoparticles have also shown to be useful 
MRI contrast agents. In contrast to gadolinium, they are superparamagnetic materials and 
yield a T2 contrast. Commercial iron oxide nanoparticles are Feridex, Resovist, and 
Combidex, and they have shown to be less toxic than Gd-based agents41, 150. One of the 
first iron oxide nanoparticles used for MRI was a cross-linked iron oxide (CLIO) which 
consisted of a cross-linked dextran functionalized with amine groups151. Fe2O3 and Fe3O4 
have been conjugated to NIR fluorescent dyes such as Cy5.5 and shown to be useful 
MRI/optical imaging agents for imaging structures such as sentinel lymph node and brain 
imaging, with low toxicity (Figure 2.9)151-152.  
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Figure 2.9 Iron oxide nanoparticles conjugated to cu-DOTA and Cy5.5 allow for triple 
modality imaging with MRI, PET, and NIR fluorescence. (A) Schematic of 
multimodal nanoparticle. (B) (i) NIR fluorescence,  (ii) PET, and (iii) MR 
images of mice 18 hours after  injection of nanoparticles152b. 
Iron oxide has also been paired with gold nanoparticles for optical/MR imaging as 
well as photothermal therapy of cancer cells using both Fe2O3112b, 112d and Fe3O4153. 5 nm 
gold particles have an absorption cross section that is 3 nm2, which is two times as high 
as a common organic fluorophore154. Additionally, because of the gold nanoparticles’ 
high absorption cross section, they provide excellent photoacoustic imaging contrast 
owing to thermoelastic expansion155. Gold coated carbon nanotubes (GNTs) have also 
been developed for both efficient photoacoustic and photothermal signal, resulting in 100 
times NIR contrast over control in lymphatic vessels with 300 nm spatial resolution156. 
These GNTs have also been used in combination with PEGylated magnetic nanoparticles 
to capture circulating tumor cells in vivo via an externally applied magnet and to image 
the captured cells photoacoustically157.  
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2.3.1.3 19F MRI agents 
Quantum dots with perfluorodecalin nanoemulsions have also been developed for 
dual 19F-based MRI and optical imaging and have been shown to be delivered 
intracellularly both to phagocytic and non-phagocytic cells158. 
2.3.2 MRI/SPECT 
Single photon emission computed tomography (SPECT) involves imaging gamma 
rays emitting from a nucleus, with the most common isotope being 99mTc, which has a 
half-life of six hours. This is long enough for tumor accumulation but short enough to 
expose the patient to only minimal amounts of radiation. 99mTc with a phospholipid layer 
of Gd chelates have been used to reveal tumor neovasculature that was asymmetric and 
patchy159. 
2.3.3 MRI/PET 
Positron emission tomography (PET) detects radiopharmaceuticals that emit 
positrons when they are activated140. PET is very sensitive and MRI has excellent spatial 
resolution. The difficulty in combining these techniques together, however, is the fact 
that conventional photomultiplier tubes that are used for PET do not operate in the high 
magnetic field required by MRI142. One way researchers have avoided this complication 
was to use a fiber optic light guide to direct certain components of the PET to avoid the 
magnetic field160. Another challenge is that MRI typically requires high doses of contrast 
agent while PET needs only trace amounts154. An MRI/PET agent consisted of 
manganese iron oxide nanoparticles and isotope I24 161. Manganese showed to have a two 
to three times higher relaxivity coefficient than iron oxide nanoparticles without 
manganese.  
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Recently, a triple modality probe used for PET/MRI/fluorescence consisted of a 
cross-linked iron oxide-TAT peptide that was cross-linked with aminated dextran for 
MRI, then attached to lysine fluorescein for optical imaging and DTPA with In for 
radioactive nuclear imaging162. 
As advances are made in developing these inorganic nanoparticles, their 
biodistribution, biocompatibility, and reproducibility must be characterized154. The next 
step is to combine these multimodal probes with a therapeutic component. Advances in 
instrumentation will also be necessary to have these agents be widely used. 
2.4 CLEARANCE OF NANOPARTICLES FROM THE BODY 
New nanoparticles and nanoparticle conjugates are constantly being developed, 
and their success in vivo depends critically on their biocompatibility and clearance 
properties44. Because nanoparticles often contain heavy metals, they could pose a toxicity 
concern if they are retained in vivo for a long time. Additionally, they could interfere 
with diagnostic imaging tests conducted over time. Nanoparticles with optimal clearance 
kinetics would minimize risks associated with toxicity by minimizing the exposure of 
these materials to the body.  
Properties known to affect clearance are material, shape, size, and surface 
chemistry44. After intravenous administration, nanoparticles encounter blood cells, 
platelets, and a variety of proteins44. If a particle traveling in the blood is opsonized, the 
effective particle size increases and this is inversely related to renal filtration. Blood 
vessel are lined with an endothelial layer which serves as a selective barrier for 
transporting macromolecules between the vascular region and the extravascular space163. 
This barrier has an effective pore size of 5 nm164. Thus, molecules with a diameter of 5 
nm or less rapidly achieve equilibrium with the extravascular extracellular space (EES), 
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while larger particles cannot pass the endothelial barrier and have a longer blood 
circulation time. In comparison, lymphatic vessels are slightly more permeable, allowing 
particles < 6 nm to pass165. 
Modifying the surface of a nanoparticle is a common method to alter their in vivo 
clearance kinetics, such as with the common procedure of PEGylating the surface of a 
nanoparticle to increase circulation as well as particle elimination166.  
2.4.1 Clearance through the kidney 
The desired excretion path for a nanoparticle is through the kidneys because there 
is minimal intracellular catabolism taking place in the kidneys, and thus there is minimal 
chance of retention. In contrast, the hepatobiliary route involves modification by 
intracellular enzymes44. Nanoparticles flowing through the glomerular capillary wall of a 
kidney will enter filtration slits which have effective pore sizes of about 4.5-5 nm167. 
Typically, molecules of < 6 nm are filtered, but 8 nm are not. Molecules 6-8 nm can be 
filtered if their surface charge is favorable44. For example, insulin, with a hydrodynamic 
diameter (HD) of 3 nm, achieves 100% filtration, with a half-life of only 9 minutes168. 
But an Fab fragment of an antibody, with a HD of 6 nm, achieves only 9% filtration with 
a serum half-life of 28 minutes169, while whole antibodies of HD 11 nm have a serum 
half-life of days. A less researched path of renal filtration is excretion through resorption 
of substances to the proximal tube of the functional unit of the kidney, the nephron. This 
is the path that glucose takes to be excreted in urine. Few studies have been done to 
characterize this path, but Kobayashi and colleagues have shown that polyamine 
dendrimers can undergo this proximal tube resorption170. 
 43
2.4.2 Clearance through the liver 
When nanoparticles do not undergo renal clearance, they most likely undergo 
hepatobiliary clearance. One of the liver’s main functions is to clear the body of particles 
10-20 nm in size which are of the size of viruses164, and even though this process of 
uptake by the liver is quick, the process of excretion is interestingly very slow164. In the 
liver, particles undergo a breakdown and are excreted through bile44.  
Phagocytic Kupffer cells in the liver have stellated branches that are mechanical 
traps for unwanted substances in blood like opsonized particles44. These Kupffer cells are 
part of the reticuloendothelial system (RES) and remove particles via degradation. If 
particles are not degraded, they will remain in the body. The turnover rate of Kupffer 
cells has been shown to be 21 days171. Hepatocytes also play an important role in clearing 
foreign particles from the bloodstream through endocytosis and enzymatic breakdown. 
The capacity of this hepatocytic breakdown, however, is much less than in Kupffer 
cells44. 
2.4.3 Nanoparticle types 
2.4.3.1 Dendrimers 
Larger-sized nanoparticles were first used in magnetic resonance (MR) 
angiography when small gadolinium (Gd) chelates were cleared too quickly from the 
blood to be useful as imaging agents142. Thus, dendrimers served as delivery vehicles of 
MR contrast agents to increase circulation time172. Because commonly used dendrimers 
such as PAMAM and poly(propyleneime) are usually 3-10 nm, their major clearance 
route is through the kidneys173. 60% of dendrimers DAB-G3-DAB-G2 and PAMAM-G2-
based contrast agents clear from the body in 15 minutes174. Interestingly, even though the 
DAB dendrimer accumulates in the liver more than the PAMAM dendrimer, the DAB 
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clears faster, which could be because DAB has a shorter interior structure than 
PAMAM174. 
2.4.3.2 Inorganic biodegradable nanoparticles 
Biodegradable macromolecular structures have been conjugated to low molecular 
weight Gd-chelates to yield longer vascular retention times and then over time degrade to 
allow for renal filtration175. Biodegradable polydisulfide Gd (III) complexes have been 
developed to serve as long-circulating carriers and can also degrade via endogenous 
thiols (glutathione, cysteine, and homocysteine), which have been known to exchange 
with disulfides176.  
2.4.3.3 Quantum dots 
Quantum dots of 5.5 nm or less showed clearance from a mouse body at 50% in 
four hours (Figure 2.10)164. The serum half-life of these quantum dots increased linearly 
with increasing size from 4.36 – 8.65 nm. The surface charge of the quantum dots played 
a large role in protein adsorption. Anionic (DHLA-coated) and cationic (cysteamine-
coated) quantum dots led to protein adsorption, increasing the HD > 15 nm, but 
zwitterionic coatings (cysteine) allowed the quantum dots to remain small, water soluble, 
and free from protein adsorption after four hours of incubation with 100% serum at 37°C. 
Thus, a zwitterionic coating was chosen as the optimal surface coating for renal 
clearance. Neutral PEGylated quantum dots did not lead to protein adsorption but could 
not be synthesized smaller than 10 nm. 
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Figure 2.10 Exposed mouse bladders 4 hours after intravenously injecting varying sizes 
of quantum dots. Top row: Color video of bladders injected with increasing 
sizes of quantum dots (left to right). Middle row: Fluorescence images of 
top row. Bottom row: Fluorescence images of unininjected control bladder. 
Scale bar is 1 cm164. 
Another study confirmed that surface coating played a major role in clearance. 
Fischer and colleagues saw that conjugating bovine serum albumin (BSA) to quantum 
dots (> 8 nm) quickened hepatobiliary clearance compared to unconjugated quantum 
dots177.  
2.4.3.4 Carbon nanoparticles 
Conjugates of Gd and C60 showed urinary excretion one hour after injection46. 
Single walled carbon nanotubes (SWCNTs) showed improved relaxivity values 
compared to conventional MRI agents and also possessed intrinsic NIR fluorescence 
along with distinct Raman signatures for multimodal imaging178. These SWCNTs have 
shown fast particle clearance with a particle half-life of three hours179. 
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2.4.3.5 Liposomes 
Reports have shown that liposome clearance is dominated by opsonins from the 
complement system180. Thus, anionic and cationic liposomes are typically found in the 
liver181. Increasing liposomal size has shown to increase clearance from blood into the 
liver180b. Compared to free contrast agents, liposomal contrast agents for computed 
tomography and MRI have shown to increase circulation half-life substantially, to ~18 
hours182. 
2.4.3.6 Gold nanoparticles 
1.9 nm gold particles in mice have shown half-lives of 2-10 minutes. After 15 
minutes post injection, the highest gold content was found in the kidneys, and after five 
hours, 77.5% of the gold had been cleared183. A study looking at a wide range of gold 
nanoparticle sizes 10-250 nm in diameter showed that 24 hours after injection, 10 nm 
particles were found mostly in the liver, blood, and spleen as well as throughout many 
other organs, while in contrast, 50-250 nm particles were found exclusively in the liver, 
spleen, and blood94.  
Gold-dendrimer PAMAM conjugates were synthesized in sizes of 5-22 nm with 
different surface charges: positive, negative, and neutral, and showed that renal clearance 
occurred for 5 nm particles but decreased as nanoparticle size increased. Regarding 
surface charge, renal clearance was maximum for positively charged particles with 36% 
injected dose of 5 nm positively charged particles in urine after five days. In contrast, 
negatively and neutral-charged 5 nm particles showed only ~8% injected dose in urine in 
the same time frame184. 
Another study showed that 2 nm glutathione capped gold particles were cleared 
renally, with 50% of the injected dose found in the urine after 24 hours. In comparison, 
cysteine, citrate, and PEGylated particles showed a much lower renal clearance185. 
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2.4.3.7 Magnetic nanoparticles 
Magnetic nanoparticles have shown to be taken up by macrophages and are thus 
good MRI markers for inflammatory diseases186. Intravenous injection of magnetic 
nanoparticles have shown to clear via the reticuloendothelial system (RES), with blood 
half-lives ranging from 1-36 hours186.  
Biodistribution has shown to depend on size, with ultra-small superparamagnetic 
iron oxide (USPIO) nanoparticles distributing in both lymph nodes and the RES, while 
larger SPIOs distribute only in the RES. Coatings have shown to play a large role in 
distribution as well, where magnetic nanoparticles coated in dextran showed a higher 
accumulation in a liver (75% of the injected dose) than magnetic nanoparticles coated in 
oleic acid and pluronic polymer (55% injected dose)187. 
Another study showed that a 30 nm USPIO nanoparticle coated in low molecular 
weight dextran led to urinary excretion of about 89% injected dose after 56 days. The 
iron was found to be incorporated into the body store of iron in the form of 
hemoglobin188.  
2.4.3.8 Silica nanoparticles 
Luminescent mesoporous silicon nanoparticles 126 nm in diameter with 5-10 nm 
pore sizes have been developed for in vivo imaging and have been shown to degrade into 
biocompatible, renally clearable components of orthosilicic acid Si(OH4)189. These 
particles completely cleared from a mouse in 4 weeks189b. 
Studies have shown that optimal characteristics of nanoparticles for efficient 
clearance must be < 6 nm in size with either a zwitterionic or cationic surface charge44. 
Because of the wide variety of nanoparticles being developed, however, agent-specific 
studies must be determined to ensure minimal toxicity and effective clearance. 
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Chapter 3: Plasmonic Nanoparticles for Treating Cancer 
3.1 INTRODUCTION 
The epidermal growth factor receptor (EGFR) is overexpressed in 80% of all non-
small cell lung cancer cells and is associated with poor survival190. Since the early 
2000’s, EGFR-targeted inhibitors have been used as therapeutic molecules in the 
clinic191. These therapeutic molecules, however, have only induced modest increases in 
patient survival on average, compared to standard non-targeted treatments. This is one of 
the reasons why lung cancer remains the leading cause of cancer-related deaths for both 
men and women1. To overcome this limitation in targeted therapeutic efficacy, we 
employed nanoparticles as an efficient delivery vehicle for the therapeutic molecules and 
a bright signal to monitor the therapeutic molecules’ interactions with target cells. This 
chapter will detail studies involved in analyzing the interactions between therapeutic 
molecules conjugated to the surface of hybrid core/shell iron oxide/gold nanoparticles 
and implications for diagnosing and treating cancer. A majority of this chapter was 
recently published in the journal PLoS One192. 
3.1.1 Nanoparticles for treating cancer 
Recently, nanoparticles have shown to enhance the effect of traditional therapies 
as well as provide therapy based on their own intrinsic properties. Nanoparticles provide 
an attractive platform for therapeutic applications because of their small size, which is 
similar to biological molecules such as viruses and proteins that can evade the 
reticuloendothelial system (RES) and gain intracellular access. 
Additionally, nanoparticles can be composed of multiple materials (organics and 
inorganics) and can provide a surface for conjugating a variety of biomolecules such as 
antibodies, nucleic acids, and polyethylene glycol (PEG). Plasmonic nanoparticles also 
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have very unique optical properties. Plasmonic gold nanoparticles have a very high 
absorption cross section, and thus have been used for photothermal therapy112b, 127a, b, 127d, 
e, 128, 193 and hyperthermia-induced killing of cancer cells138-139. Because of their small 
size and thus large surface area to volume ratio, NPs have also acted as delivery vehicles 
for drugs62d, 131-132. More details of these studies can be found in Chapter 2.2.3. 
3.1.2 Multivalency 
Targeted therapeutics have shown only modest increases in treating cancer194. 
Two ways that can improve on this disappointing therapeutic effect is to monitor the 
therapeutic molecule in the body to determine as early as possible if the therapeutic 
molecule is arriving at its desired destination, and to increase the binding affinity of these 
therapeutic molecules to its target. Both these goals can be accomplished using a single 
entity: nanoparticle technology. 
Plasmonic nanoparticles such as gold nanoparticles have already been shown to 
be robust contrast agents in optical imaging modalities which have high spatial resolution 
that can be monitored over time195. Thus, gold nanoparticles can serve as bright monitors 
of therapeutic molecules in vivo. 
Increasing the binding affinity of therapeutic molecules can be accomplished by 
increasing the valency of the therapeutic molecule. In 1972, Crothers and Metzger 
calculated an increase in observed equilibrium constant for forming a bond between an 
antibody and its antigen as antibody valency increased196. Since then, molecules have 
shown to target more effectively if the valency of the molecule is increased197. In the 
early 2000’s, this multivalent enhancement was exploited to show that polyvalent 
inhibitors were able to bind to toxins and inhibit them from binding to their target cells 
more effectively than univalent inhibitor molecules. In 2000, Kitov and colleagues 
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showed that an oligovalent carbohydrate ligand of less than 10 nm bound 1-10 million 
times more strongly to Shiga-like toxins than univalent Pk trisaccharides, and more 
effectively than the toxins to their target, showing that multivalent ligands can act as 
extremely potent inhibitors of toxin198. Similarly, a year later, Mourez and colleagues 
showed that by attaching an anthrax-inhibiting peptide to a polyacrylamide backbone, 
they achieved a 7,500 fold increase in inhibition of anthrax per peptide over free 
peptide199. 
Multivalency has also been used to increase targeting to cancer cells. Folic acid 
has been used as a targeting agent on polymeric nanoparticles and showed an increased 
uptake in cancer cells than free folic acid200. To quantify this binding avidity, Hong and 
colleagues decorated dendrimer nanoparticles with folate molecules and showed an 
enhanced dissociation constant of multivalent nanoparticles compared to free folate, 
ranging from 2,500-170,000 times for increasingly multivalent particles201. An in vivo 
study showed that by decorating 26 nm gold nanoparticles with tumor necrosis factor 
(TNF), a decrease in tumor size was obtained compared to free TNF202. Moreover, these 
type of conjugates showed less systemic toxicity than free TNF203. More recent studies 
have shown that there is an optimal density of targeting ligand that can be decorated on 
the surface of a nanoparticle to maximize targeting204. Poon and colleagues determined 
that an optimal density of 3.1 folate groups per micelle led to the highest uptake of cells 
overexpressing the folate receptor, compared to more densely and less densely packed 
folate groups. Each micelle type had the same total number of folates per micelle. 
Thus, many studies have shown that multivalent molecules can lead to an 
enhanced binding and effect on their targets compared to free molecules. 
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3.2 MATERIALS AND METHODS 
3.2.1 Cell culture 
Human non-small cell lung cancer (NSCLC) cells (H1299, H1819, H1975, H3255 
HCC827) were a generous gift from Dr. John D. Minna (Department of Internal 
Medicine and Pharmacology, Hammon Center for Therapeutic Oncology Research, The 
University of Texas Southwestern Medical Center, Dallas, Texas). NSCLC cells (H520), 
lung fibroblasts (MRC-9 and WI38), and normal human bronchial epithelial (NHBE) 
cells were purchases from American Type Culture Collection (Manassas, VA). All cells 
were cultured in RPMI 1640 medium (GIBCO, Grand Island, NY) or MEM Alpha 
(GIBCO) supplemented with 10% FCS (Hyclone, Logan, UT), 2mM L-glutamine, 
penicillin (50 U/mL), and streptomycin (100 µg/mL). 
3.2.2 Synthesis and conjugation of nanoparticles 
The protocol for preparing colloidal core/shell iron oxide/gold (AuFe) 
nanoparticles has been previous described in a paper by Lyon and colleagues (Figure 
3.1)205. First, iron seeds were synthesized by coprecipitation of Fe(II) and Fe(III) 
chlorides (1:2 ratio) with 1.5M NaOH as the reductant. The colloid was magnetically 
decanted, washed in DIUF water (18 MOhms) via centrifugation for 2 hours at 1500 x g, 
and resuspended in a stabilizer – 0.1M tetramethylammoinum hydroxide (TMAOH). The 
resulting colloidal suspension of 9 nm magnetite (Fe3O4) nanoparticles was oxidized in 
boiling 0.1M HNO3 followed by washing in 0.01M HNO3 and resuspension in 0.1M 
TMAOH. The final colloidal suspension had ~36 mM, γ Fe2O3 at pH 12 with a particle 
diameter of ca.9 nm. N(CH3)4+ and OH- ions stabilized the suspension, preventing 
aggregation. A gold coating was formed by reducing HAuCl4 on the surface of the iron 
using an iterative hydroxylamine process under UV-Vis spectroscopy monitoring that 
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showed a gradual increase in plasmon resonance peak characteristic for spherical gold 
nanoparticles. Right after synthesis, AuFe nanoparticles exhibited a jagged appearance 
because of the fact that Au3+ ions initially reduce onto specific sites of the iron oxide 
nanoparticles, and over time, will fill the bare space and create a more uniform surface205. 
 
 
Figure 3.1 Schematic of process of coating iron oxide nanoparticle (5-10 nm) with a 
gold shell, yielding ~50 nm total diameter205.  
The antibody conjugation procedure was followed as previously described in a 
paper by Kumar and colleagues (Figure 3.2)67. Briefly, monoclonal antibodies were 
attached to the gold surface via a linker (SensoPath Technologies) that consisted of a 
short polyethylene glycol (PEG) chain terminated at one end by a hydrzide moiety, and at 
the other end by two thiol groups. First, antibodies at a concentration of 1 mg/mL were 
exposed to 10 mM NaIO4 in a 40 mM HEPES pH 7.4 solution for 30-40 minutes at room 
temperature, thereby oxidizing the hydroxyl moieties on the antibodies’ Fc region to 
aldehyde groups. The formation of the aldehyde groups was colorimetrically confirmed 
using a standard assay with an alkaline Purpald solution. Then, excess hydrazide-PEG-
thiol linker was added to the oxidized antibodies and was allowed to react for 20 minutes. 
The hydrazide portion of the PEG linker interacts with aldehyde groups on the antibodies 
to form a stable linkage. In this procedure, a potential loss of antibody function is avoided 
because the linker cannot interact with the antibody’s target-binding region, which 
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contains no glycosylation. The unreacted linker was removed by a 100,000 MWCO 
centrifugal filter (Millipore). After purification, the modified antibodies were mixed with 
nanoparticles in 40 mM HEPES (pH 7.4) for 20 minutes at room temperature. During this 
step, a stable bond is formed between the gold surface and the linker’s thiol groups. 
Subsequently, 5% by volume of 10-5 M 5kD methoxyPEG-SH (Creative PEGWorks) in 
water was mixed for 5 minutes with antibody/nanoparticle conjugates to cap remaining 
bare surfaces of nanoparticles. Then, 2% by weight PEG (Sigma-Aldrich) solution was 
washed twice at 1500 x g for 20 minutes. Final conjugates were resuspended in 2% PEG 
in PBS. 
 
Figure 3.2 Schematic of antibody conjugation to nanoparticle surface. Top row: Dithiol 
linker is covalently attached to an antibody only on Fc portion of the 
antibody. Bottom row: Antibody+linker attached to nanoparticle surface via 
the dithiol linker, leaving the Fab targeting portion of the antibody free. 
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For varying the density of Clone 225 antibodies on the surface of the 
nanoparticles (Figure 3.3), a fluorescence technique was used. Nanoparticles were 
conjugated with anti-EGFR antibodies [Clone 225 monoclonal antibody, (host mouse; 
Sigma-Aldrich, St. Louis, MO)], anti-rabbit IgG monoclonal antibody (Clone RG-16, 
Sigma-Aldrich, St. Louis, MO) or with a mixture of the two antibodies at ratios of anti-
EGFR:anti-rabbit Abs of 1:0, 1:1, 1:3, 1:10, 1:40, and 0:1. To achieve different antibody 
ratios at the surface of the nanoparticles, antibodies were pre-mixed at the desired ratio 
before adding to the nanoparticle suspension. The composition of Clone 225 and anti-
rabbit IgG antibodies on the surface of the nanoparticles was verified using fluorescent 
assay. Clone 225 antibodies and anti-rabbit antibodies were labeled using Alexa Fluor 
488 and Alexa Fluor 594, respectively. Then, calibration curves were measured to 
determine the concentration of labeled antibodies using fluorescent intensity. The 
fluorescent intensities of antibody solution at the excitation/emission wavelengths of the 
two Alexa fluorophores were measured at the concentration that was used for conjugation 
with nanoparticles and were compared with fluorescence intensities of the supernatant 
after nanoparticle/antibodies conjugates were spun down. The ratio of the difference in 
signal between the pre- and post-conjugation intensities was calculated and was used to 
confirm the composition of both antibodies on the surface of the nanoparticles. 
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Figure 3.3 Schematic of nanoparticles with varying ratios of therapeutic anti-EGFR 
antibodies (blue antibodies) to nonspecific anti-rabbit IgG antibodies (red 
antibodies). 
3.2.3 Cell viability assay 
The cytotoxic effect of Clone 225-nanoparticles (Clone 225-NP) on NSCLCs and 
normal cells was determined by using a trypan blue dye exclusion assay. Cancer or 
normal cells were seeded at 1 or 2x105 cells/well in 6-well plates and incubated overnight 
at 37°C. The cells were then incubated for 72 hours with/without IgG-NP (6x109 
particles), Clone 225-NP (6x109 particles), or Clone 225 antibody (0.0065 µg/mL). After 
the cells were collected by trypsinization, they were stained with trypan blue, and the 
viable cells in each well were counted. The viability of the untreated cells (the control) 
was considered 100%. Survival fraction were calculated from the mean cell viability of 
the treated cells over control and the relative difference in cell number expressed as 
percent of cell killing over control. 
3.2.4 Apoptosis detection assays 
Tumor cells that were untreated or treated with Clone 225 antibody, IgG-NP, or 
Clone 225-NP were collected at 72 hours after treatment, fixed with 70% ethanol, and 
stained with 10% propidium iodide solution (Roche cellular DNA flow-cytometric 
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analysis reagent set: Indianapolis, IN) according to the manufacturer’s instructions. DNA 
content was analyzed with a FACScan flow cytometer (Becton Dickinson) as previously 
described in a paper by Ramesh and colleagues206. Data were analyzed with the 
manufacturer’s CellQuest software. 
3.2.5 Autophagy detection assay 
Using the GFP-LC3 expression vector (LC3 cDNA kindly provided by Dr. N. 
Mizushima (Department of Physiology and Cell Biology, Tokyo Medical and Dental 
University), the involvement of LC3 in tumor cells treated with control IgG-NP cells 
were transfected with the GFP-LC3 expression vector using FuGENE 6 transfection 
reagent (Roche Applied Science). After overnight culture, cells were treated with IgG- or 
Clone 225-NP fixed with 4% paraformaldehyde, and examined under an Axioskop 40 
fluorescence microscope. To quantify autophagic cells after treatment, we counted the 
number of autophagic cells among 100 GFP-positive cells. 
3.2.6 Cell cycle analysis 
HCC827 cells were treated with three difference concentrations (1.5, 2.44, and 
3.55 ng/mL) of free Clone 225 antibodies or Clone 225-NP (0.6, 1.2, and 2.4x1010 
particles). The amount of free Clone 225 antibody added was at equimolar concentrations 
with antibodies attached to nanoparticles. Untreated cells served as controls. At 72 hours 
after treatment, cells were harvested and the number of cells in the sub-G1 phase of the 
cell cycle was determined by DNA flow-cyotmetric analysis206. 
3.2.7 Western blotting 
Untreated or treated cells were lysed in extraction buffer and the soluble proteins 
were isolated as previously described in a paper by Yokoyama and colleagues207. Protein 
concentrations were estimated using a protein assay (Bio-Rad, Richmond, CA), and 
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proteins were separated by sodium dodecyl sulfate-7.5 to 15% polyacrylamide gel 
electrophoresis (SDS-PAGE) and transferred electrophoretically to Hybond-P membrane 
(Amersham, Piscataway, NJ). The membrane was subjected to Western blotting using 
anti-LC3B antibody (1:5,000 dilution), anti-PARP antibody (1:1000 dilution; Cell 
Signaling Technology, Beverly, MA), anti-phospho/total-EGFR antibody (1:500 dilution; 
Santa Cruz Biotechnology, Santa Cruz, CA), anti-phosphorylated/total-AKT, p38 
MAPK, and p44/42 MAPK antibodies (1:1000 dilution; Cell Signaling Technology), and 
mouse anti-β-actin antibody (1:500 dilution; Sigma-Aldrich). Anti-LC3 antibody was 
generated as previously described208. Immunoreactive proteins were detected using an 
enhanced chemiluminescence reagent (Amersham) according to the manufacturer’s 
instructions. 
3.2.8 TEM of cells 
HCC827 cells were seeded onto 6-well plates (1x105 cells/well) and were treated 
with Clone 225 antibody for 72 hours, IgG-NP or Clone 225-NP (6x109 particles) for 48 
or 72 hours and then fixed with a solution containing 3% glutaraldehyde plus 2% 
paraformaldehyde in 0.1M cacodylate buffered tannic acid, postfixed with 1% buffered 
osmium tetroxide for 30 minutes, and stained en bloc with 1% Millipore-filtered uranyl 
acetate. The samples were dehydrated in increasing concentrations of ethanol, infiltrated, 
and then embedded in Poly-bed 812 medium. The samples were polymerized in a 60°C 
oven for 2 days. Ultrathin sections were cut in Leica Ultracut microtome (Leica, 
Deerfield, IL), stained with uranyl acetate and lead citrate in Leica EM Stainer, and 
examined with a JEM 1010 transmission electron microscope (JEOL, USA, Inc., 
Peabody, MA) at an accelerating voltage of 80 kV. Digital images were obtained using 
AMT imaging system (Advanced Microscopy Techniques Corp., Danvers, MA). To 
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quantify autophagic cells after treatment, we counted the number of autophagic cells per 
100 mm2 cytoplasm, as previous described209. 
3.2.9 Optical imaging 
NSCLC cells and normal cells were resuspended in phenol-free RPMO medium 
and were seeded in two-well chamber slides. These cells were treated with IgG-NP or 
Clone 225-NP in the absence or presence of free unbound Clone 225 antibody (2 µg/mL). 
At 24 hours after treatment, cells were washed, fixed in 1% paraformaldehyde, and 
imaged using dark-field (DR) reflectance microscopy. All DR images were acquired 
using Leica, DM6000 microscope equipped with 20x DR objective and Xenon lamp 
white light illumination. 
Confocal images were acquired with a Leica SP2 AOBS confocal microscope 
using a 63x oil immersion objective, 1.4 NA (Leica Microsystems, Bannockburn, IL). 
Images were taken every 0.25 µm with a total depth of 55 µm. A 633 nm red HeNe laser 
was used for detection of nanoparticles in reflectance mode and a UV 350 nm laser 
excitation was used to measure DAPI fluorescence. A 3D rendering of the confocal 
images was obtained using the volume rendering program Voxx (Indiana Center for 
Biological Microscopy). 
3.2.10 Immunohistochemistry of EGFR expression 
HCC827 cells (2x103) seeded in two-well chamber slides were treated with IgG-
NP or Clone 225-NP (2x109 particles). At 30 minutes after treatment, chamber slides 
were washed in phosphate buffered saline (PBS), fixed in 0.1% glutaraldehyde and 
subjected to immunohistochemical staining using monoclonal antibodies against human 
phosphorylated and total EGFR (Santa Cruz Biotechnology) and Vectastain kit (Vector 
laboratories, Burlingame, CA). Untreated cells served as controls. The expression of 
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phosphorylated and total EGFR in cells after NP treatment was captured by bright-field 
microscopy and reduction in phosphorylated EGFR determined by semi-quantitative 
analysis. 
3.2.11 Statistical analysis 
Data are expressed as means and 95% CI. The statistical significance of the 
differences in the in vitro antitumor effects of Clone 225 antibody, IgG-NP, and Clone 
225-NP was determined by using Student’s two-tailed t test. 
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3.3 RESULTS 
3.3.1 Nanoparticle characterization 
The process of synthesizing the nanoparticles was characterized with UV Vis and 
TEM (Figure 3.4). 
 
Figure 3.4 Monitoring synthesis of core/shell iron oxide/gold nanoparticles. (a) UV-Vis 
spectra of iron oxide nanoparticles (brown curve), AuFe right after synthesis 
(red curve) which has a jagged appearance owing to the fact that the Au3+ 
ions initially reduce onto specific sites of the iron oxide nanoparticles, and 
then over time, the gold fills the surface, and AuFe after 1-2 days (purple 
curve). (b) Left to right: TEM images of iron oxide nanoparticles, AuFe 
right after synthesis, and AuFe 1-2 days after synthesis.  (c) Left image 
shows AuFe nanoparticle pellet being manipulated by a magnet, while in the 
right image, solid Au nanoparticle pellet cannot be manipulated, 
demonstrating magnetic properties of the AuFe nanoparticles. 
The nanoparticles with and without conjugated antibodies were characterized for 
size and charge using UV Vis spectroscopy, transmission electron microscopy (TEM), 
dynamic light scattering (DLS), and zeta potential measurements. UV Vis spectroscopy 
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revealed a slight red shift in the spectrum after conjugating antibodies to the surface 
(Figure 3.5). This red shift occurs because of a local change in index of refraction caused 
by the conjugation of the antibody.   
 
 
Figure 3.5 UV Vis spectra of bare AuFe nanoparticles and antibody conjugated AuFe. 
Conjugated nanoparticles spectrum is slightly red-shifted compared to bare 
nanoparticles because of a local change in index of refraction. 
TEM, DLS, and zeta potential measurements are summarized in Figure 3.6. TEM 
analyses showed that the gold coated iron oxide nanoparticles have sizes of 51±13 nm 
before and 54±11 nm after antibody conjugation. No apparent change in the sizes of 
nanoparticles in TEM images is expected as antibody coating does not result in an 
electron dense layer that would be visible in TEM. DLS measurements showed an 
increase in nanoparticle sizes from 51±25 nm to 73±35 nm after conjugation of 
antibodies; this result is consistent with our previous measurements of 
nanoparticle/antibody conjugates112d. Antibody conjugation also resulted in an increase of 
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surface charge from -53±3 mV to -29±1 mV as antibody and PEG molecules replaced 
citrate ions from the surface of the citrate stabilized AuFe nanoparticles. 
 
 63
 
Figure 3.6 TEM, DLS, and zeta potential measurements of AuFe nanoparticles. (A) 
Low magnification (left) and high magnification (right) TEM images of 
antibody (Ab) conjugated AuFe nanoparticles. (B) Size distribution of AuFe 
nanoparticles before and after Ab conjugation reveal nanoparticles size of 
~50 nm. There is little change in size before and after antibody conjugation 
as measured by TEM because an Ab is not an electron dense material and 
thus provides little contrast in TEM image (n= at least 96 particles). (C) 
DLS measurements, volume distribution of AuFe nanoparticles before and 
after conjugation with Abs (n=3). (D) Zeta potential measurements reveal 
negatively charged bare AuFe nanoparticles, and as expected, a less 
negatively charged particles after conjugation with Abs. 
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3.3.2 225-NP enhances cell killing 
3.3.2.1 Cell lines and EGFR/pEGFR expression levels 
Epidermal growth factor receptor (EGFR), both phosphorylated and total, 
expression were examined on several human non-small cell lung cancer (NSCLC) cells 
using Western blotting. NSCLC cells were wild type (H1299), mutated and 
overexpressed (HCC827, H1975, and H3255), amplified (H1819), or null (H520). 
Normal cells were lung fibroblasts (MRC-9 and WI38) and normal human bronchial 
epithelial (NHBE) cells. 
Phosphorylated EGFR (pEGFR) and EGFR were detected in all cell lines except 
the EGFR-null cell line H520. pEGFR varied with NSCLC that expressed high levels of 
EGFR (HCC827, H4355, and H1819) (Figure 3.7a). Wild type H1299 cells had a 
medium level of expression of pEGFR. All normal cells (MRC-9, WI38, and NHBE) as 
well as mutated and overexpressed H1975 interestingly enough showed low levels of 
pEGFR. 
3.3.2.2 Cell death 
Adding Clone 225 conjugated nanoparticles (225-NP conjugates) to highly 
pEGFR-expressing HCC827, highly pEGFR-expressing H1819, and medium pEGFR-
expressing wild type H1299 cells yielded significant cell death compared to control non-
specific IgG-NP conjugates (p<0.05) (Figure 3.7b). The 225-NP conjugate-mediated cell 
killing effect was independent of EGFR mutational status. No significant cell death was 
seen with EGFR-null H520 cells treated with 225-NPs. Among the normal cell lines, 
normal lung fibroblasts MRC-9 showed some inhibitory effects, 9%, but this was less 
than the cytotoxic effect on the NSCLC cells, which was 14-18%. No effect was 
observed with normal human bronchial epithelial NHBE cells.  
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Figure 3.7 Effect of EGFR-targeted 225-NP treatment on NSCLC cells. (a) Expression 
of phosphorylated and total EGFR in normal and NSCLC cells. (b) Cell 
killing in response to EGFR-targeted 225-NP on NSCLC and normal cells. 
Results shown are the means ± S.D. of three independent experiments. *P-
value<0.05 vs. IgG-NP on H1299, HCC827, and H1819 cells. 
3.3.2.3 Protein expression 
Protein expression was then assessed in the cells after being treated with either 
225-NP or non-specific IgG-NPs. For high pEGFR-expressing HCC827 cells and 
medium pEGFR-expressing wild type H1299 cells treated with 225-NPs, a reduced 
expression of pEGFR, AKT (Protein Kinase B, which inhibits apoptotic processes), 
p38MAPK, and p44/42MAPK (mitogen-activated protein kinase, which is involved in 
cell differentiation) was observed compared to non-specific IgG-NPs treated cells (Figure 
3.8). 
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Figure 3.8 225-NP regulated EGFR signaling pathway in tumor cells but not in normal 
cells. Inhibitory effects of 225-NPs on phosphorylated EGFR (pEGFR) and 
the downstream signaling molecules involved in human lung cancer and 
normal cells. 225-NP treatment reduced the expression of the 
phosphorylated (p) forms of EGFR, AKT, p38MAPK, and P44/42MAPK in 
EGFR-positive tumor cells but not in normal cells. There was no effect on 
EGFR-null H520 cells. 
pEGFR was markedly reduced by 35% (p<0.05) as shown by 
immunohistochemical staining in high pEGFR-expressing HCC827 cells treated with 
225-NP, compared to non-specific IgG-NPs at 30 and 60 minutes after treatment (Figure 
3.9). There was no marked reduction in pEGFR or other proteins that are involved in cell 
growth in normal cells (MRC-9 and NHBE) treated with either 225-NPs or non-specific 
IgG-NPs. 
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Figure 3.9 225-NP reduces phosphorylated EGFR (pEGFR) expression in NSCLC 
cells. IgG-NP or 225-NP-treated cells were stained for EGFR by 
immunocytochemistry. pEGFR expression was reduced in both IgG-NP and 
225-NP-treated HCC827 cells when compared to untreated control cells; 
however, the reduction in pEGFR expression was significantly greater in 
225-NP-treated cells (35% reduction over untreated control cells; p-
value<0.05) than in IgG-NP-treated cells (8% reduction over untreated 
control cells).  
3.3.3 225-NP produces greater antitumor activity than individual components of 
nanoparticle 
3.3.3.1 Individual components 
Next, we determined the contribution of the individual components of the 
nanoparticles on the killing effect of tumor cells. High pEGFR-expressing HCC827 cells 
were treated with AuFe nanoparticles alone and free 225, and both individually decreased 
cell viability by 12-14% over untreated control. A combination of free 225 mixed with 
(not conjugated to) free AuFe led to cell killing of 22% (Figure 3.10a). After conjugating 
the AuFe nanoparticle surface with Clone 225 antibody, these conjugates led to 
significantly higher cell death of 48% (p<0.05) than any of the individual components. 
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3.3.3.2 Non-therapeutic anti-EGFR antibody (Clone 29.1) 
To gain more information from these conjugates’ interactions with cells, we 
conjugated the surface of AuFe nanoparticles with non-therapeutic anti-EGFR antibodies 
(Clone 29.1) and looked at these targeted yet non-therapeutic conjugates’ interactions 
with cells. While non-therapeutic Clone 29.1 antibody still binds to EGFR, the portion of 
the EGFR that Clone 29.1 binds to does not block the portion that a growth ligand EGF 
binds to. In contrast, Clone 225 does bind to a portion of the EGFR that blocks binding of 
EGF and thus inhibits growth of the cell. Clone 29.1 binds to a carbohydrate residue on 
an external portion of EGFR210. When  high pEGFR-expressing HCC827 cells were 
treated with Clone 29.1-NPs, an intermediate cell killing effect (14%) was induced which 
was significantly less (p<0.05) than 225-NP-mediated cell killing effect, but more than 
other control treatments (7-15%) (Figure 3.10b). 
 
 
 
Figure 3.10 225-NP produces a greater killing effect than individual components of 225-
NP. (a) HCC827 cells treated with 225-NPs demonstrated significant cancer 
cell killing effect compared to treatment with AuFe, 225 antibody, and a 
mixture of AuFe plus 225 antibody. *P-value<0.05. (b) Comparison of the 
inhibitory effects produced by 29.1-NP conjugates with 225-NPs on 
HCC827 cells. 225-NP treatment produced a great killing effect than 29.1-
NP treatment compared to other treatment groups. *P-value<0.05. 
 69
These results show that assembling the therapeutic antibody Clone 225 on a 
surface of a nanoparticle results in enhanced cancer cell killing effect compared to 
individual components and targeted nanoparticles that do not have a therapeutic 
component. 
3.3.4 225-NP induces both apoptosis and autophagy 
3.3.4.1 Apoptosis 
To determine the paths activated by 225-NP conjugates, we performed flow 
cytometric analyses on high pEGFR-expressing HCC827 cells and EGFR-null H520 cells 
treated with 225-NPs. The sub-G1 population, which indicates percentages of apoptotic 
cells, showed a dose-dependent response of apoptosis occurring in 225-NP-treated 
HCC827 cells (9-20%), while on non-specific IgG-NPs, there was only a 4-8% apoptotic 
population of the same cells (Figure 3.11a).  
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Figure 3.11 Induction of apoptosis and autophagy in response to EGFR-targeted 225-
NPs in NSCLC cells. (a) Percentage of NSCLC cells treated with different 
doses (0.6, 1.2, and 2.4x1010 particles) of IgG-NP or 225-NP for 72 hrs that 
was in the sub-G1 phase of the cell cycle. This percentage was determined 
by DNA flow-cytometric analysis. Untreated cells and cells treated with free 
225 antibody served as controls. A dose-dependent increase in the number 
of HCC827 cells in subG1 phase was observed in both IgG-NP and 225-NP 
treatments. The increase in number of cells in subG1, however, was 
significantly higher in 225-NP treatment than in IgG-NP (*P-value<0.05). 
There was no marked increase in subG1 phase in H520 cells between IgG-
NP- and 225-NP-treatements. (b) Detection of GFP-LC3 dots indicative of 
autophagy on NSCLC cells that were not treated or treated with 225 
antibody, IgG-NP, or 225-NPs (3x109 particles) for 72 hours on chamber 
slides. Scale bar = 5 µm. (c) Quantification of the number of cells with GFP-
LC3 dots on untreated and treated NSCLC cells. The number of cells with 
GFP-LC3 dots was higher in 225-NP-treated HCC827 cells compared to all 
other treatment groups. In H520 cells, there was no increase in the number 
of GFP-LC3 dots when treated with 225-NP and 225 antibody alone, and 
IgG-NP on HCC827 cells. 
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Clone 225 antibody alone yielded a significantly less percentage of apoptotic 
population (4-8%) compared to 225-NP-treated HCC827 cells (Figure 3.12). There was 
no increase in apoptotic population for EGFR-null H520 cells treated with either 
nanoparticle treatments (Figure 3.11a). Thus, 225-NP induced apoptosis in EGFR-
expressing HCC827 cells over EGFR-null H520 cells. 
 
 
Figure 3.12 Comparison of free Clone 225 antibody with 225-NP conjugates on their 
ability to induce apoptosis in lung tumor cells. 225-NP treatment of 
HCC827 cells resulted in a dose-dependent increase in the percentage of 
cells in the subG1 phase compared to treatment with Clone 225 antibody at 
all concentrations tested. *P-value<0.05 vs. the same concentrations of 
Clone 225 antibody. 
3.3.4.2 Autophagy 
Recently, Seleverstov showed that quantum dots induced size-dependent 
autophagy in human mesenchymal stem cells211. Thus, to further elucidate activated 
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pathways, we investigated whether autophagy was occurring with our nanoparticles. We 
examined if autophagy was occurring in our cells after treatment of cells with 
nanoparticles using a green fluorescent protein (GFP)-tagged expression vector of 
microtubule associated-light chain 3 (LC3)212. In cells undergoing autophagy, the GFP-
LC3 will distribute in a punctate distribution, sequestering in the membranes of 
autophagosomes, while a normal cell will yield an even distribution of LC3, and thus an 
even homogenous green color throughout the cell. Fluorescence images showed that high 
pEGFR-expressing HCC827 cells that did not receive 225-NP, but was transfected with 
the GFP-LC3 showed a diffuse distribution of GFP-LC3, while the same cells treated 
with 225-NP showed a punctate distribution indicating the presence of autophagic 
vacuoles (Figure 3.11b). The same even distribution was seen with control groups of non-
specific IgG-NPs and 225 antibodies alone. The percentage of cells with a punctate 
distribution increased significantly (p<0.05) with treatment of 225-NPs compared to 
untreated cells (Figure 3.11c). 
The same increase in autophagy indicated by a punctate distribution of GFP-LC3 
was also observed in medium pEGFR-expressing H1299 cells that were treated with 225-
NPs compared to control treatments (Figure 3.13). 
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Figure 3.13 225-NP induces autophagy in H1299 lung cancer cells. (a) Detection of 
GFP-LC3 dots in H1299 cells that were either not treated or treated with 
Clone 225 antibodies, IgG-NPs, or 225-NPs (3x109 particles) for 72 hours 
on chamber slides. Scale bar = 5 µm. (b) Quantitative analysis showed 225-
NP-treated HCC827 cells had a higher number of GFP-LC3 dots in 
comparison to all other treatment groups. Results shown are the means ± 
S.D. of three independent experiments. *P-value<0.05 vs. untreated control, 
Clone 225 antibody, and non-specific IgG-NP. 
3.3.4.3 PARP cleavage 
We wanted to further confirm that apoptosis and autophagy were occurring, so we 
investigated an apoptosis indicator, poly (ADP-ribose) polymerase (PARP) cleavage, and 
further studied the autophagy marker, light chain 3 (LC3) protein.  
PARP cleavage was seen at 24 hours after treating high pEGFR-expressing 
HCC827 cells with either 225-NPs or with non-specific IgG-NPs, but PARP cleavage 
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was not observed in EGFR-null H520 cells. PARP cleavage was also higher for 225-NP-
treated HCC827 compared to control nanoparticles (Figure 3.14a).  
Regarding autophagy, light chain 3 (LC3) protein exists in tow forms: LC3-I and 
LC3-II. LC3-I is converted to LC3-II by conjugation to phosphatidylethanolamine, and 
the amount of LC3-II is closely correlated with the number of autophagosomes213. High 
pEGFR-expressing HCC827 cells treated with 225-NPs showed an increase in LC3-II 
over time, indicating autophagy was occurring (Figure 3.14a). Additionally, recent 
studies have shown that LC3-II is more accurately represented in autophagic flux when in 
the presence of lysosomal inhibitors214. Thus, in the presence of protease inhibitors E-64-
d and pepstatin A, endogenous LC3-II increased in HCC827 cells after treatment with 
either IgG-NP or 225-NPs (Figure 3.14b). Again, the LC3-II amount was greater for 
HCC827 cells treated with 225-NPs compared to non-specific IgG-NPs. A similar 
increase in LC3-II was observed in medium pEGFR-expressing H1299 cells. In contrast, 
EGFR-null H520 cells treated with either nanoparticles conjugates after 72 hours did not 
show any increase in LC3-II amount, indicating autophagy was not occurring. 
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Figure 3.14 Analysis for molecular markers of autophagy and apoptosis in 225-NP-
treated cancer cells. (a) Cellular proteins were lysed at the indicated time 
after treatment with IgG-NPs or 225-NPs (6x109 particles) and subjected to 
Western blotting. In HCC827 cells but not in H520 cells, increased PARP 
cleavage and LC3-II were observed at 48 and 72 hrs after treatment with 
225-NPs and when compared with IgG-NP treatment and untreated control. 
The intensities of the amount of LC3-II bands were semi-quantified by 
ImageJ software (National Institutes of Health, Bethesda, MD). (b) 
MCC827 cells were treated with IgG-NPs or 225-NPs for 68 hrs. Cells were 
further cultured with or without protease inhibitors [10 µg/mL E-64-d and 
10 µg/mL pepstatin A (BIOMOL International L.P., Plymouth Meeting, 
PA)] for 4 hours. Cellular proteins were lysed and immunoblotted with anti-
LC3 antibody. LC3-II protein levels were increased in the presence of 
protease inhibitors in all of the groups indicating occurrence of autophagy. 
The intensities of the amount of LC3-II bands were semi-quantified by 
ImageJ software (National Institutes of Health, Bethesda, MD). 
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In conclusion, 225-NPs induced both apoptosis and autophagy in EGFR-
expressing NSCLC cells. Non-specific IgG-NPs also induced autophagy to a lesser extent 
and caused a significantly less effect of cell killing compared to 225-NPs. This difference 
is probably because 225-NPs initiate autophagy and this autophagy is strong enough to 
activate a caspase cascade and lead to apoptotic cell death, while IgG-NPs induce a lesser 
extent of autophagy which serves as a cell survival mechanism and thus does not lead to 
cell death via apoptosis.  
To further characterize the effects of 225-NPs on high pEGFR-expressing 
HCC827 cells, TEM of treated cells was performed. TEM images revealed a significant 
amount of autophagic vacuoles within HCC827 cells treated with 225-NPs compared to 
HCC827 cells treated with IgG-NPs (p<0.05) (Figure 3.15).  
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Figure 3.15 In situ localization of 225-NP in NSCLC cells. Electron micrographs 
showing the ultrastructure of a cell, including the nucleus (N), of HCC827 
cells treated with Clone 225 antibody (0.065 µg/mL), IgG-NPs, or 225-NPs 
(6x109 particles) for 72 hours. (i) Untreated cells (ii) Clone 225 antibody-
treated cells (iii) IgG-NP-treated cells (iv) 225-NP-treated cells (v) A 
magnified view of the area boxed in (iv). The arrows indicated NPs, and the 
arrowhead indicated autophagosomes that includes residual material and 
nanoparticles in the cytoplasm (vi) 225-NPs detected inside the nucleus. The 
arrow indicates nanoparticles in the nucleus. Scale bar = 1 µm. (vii) 
Autophagosomes were quantified, as describes in Materials and Methods 
(Chapter 3.2.8). *P-value<0.05 vs. controls, Clone 225 antibody and IgG-
NPs for 48 and 72 hours. 
While most 225-NPs were observed in vacuoles, a few 225-NPs were observed in 
the nuclei. This was confirmed with confocal microscopy (Figure 3.16). We did not 
quantify the number of particles in the nucleus because of limitations of using TEM and 
confocal for quantitative analysis. Because TEM has high resolution, the quantitation of 
multiple cells would be impractical. Analysis by confocal microscopy is complicated by 
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the fact that cellular uptake of the nanoparticles is mostly in the perinuclear space, and 
thus, optical resolution is not sufficient to separate the nanoparticles that are close to the 
nuclear membrane and the nanoparticles that are indeed inside the nucleus. Additionally, 
very bright objects such as gold nanoparticles can induce strong out of focus signal that 
can be misinterpreted in 3D. This limitation of 3D quantitation using confocal 
microscopy was demonstrated when the cytosolic uptake of quantum dots was 
overestimated215. 
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Figure 3.16 Detection of 225-NP localization in the nucleus by confocal microscopy. 
(Top row) Confocal images show DAPI stained nuclei (blue) and 225-NPs 
(red). Arrows in the “middle” column point to the 225-NPs localized in a 
nucleus. Arrows in the columns labeled “top” and “bottom” point to the 
same area in the xy plane of the nucleus but at locations above and below 
the middle of the nucleus, respectively. In both the “top” and “bottom” 
images, the arrows are no longer pointing at red spots which indicate that 
the red spots in the “middle” image are indeed within the nucleus. (Bottom 
row) Cartoon indicating the z position of each image within the nucleus, 
where the red horizontal line represents the relative depth position within the 
nucleus that the cross-sectional images (top row) were taken. Scale bar = 10 
µm. 
3.3.4.4 225-NPs are molecular-specific for EGFR 
Dark-field reflectance (DR) microscopy was used to characterize 225-NP 
interactions and the feasibility of optical detection of NSCLC cells. DR images showed a 
high concentration of internalized 225-NP in high pEGFR-expressing HCC827 cells after 
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24 hours after treatment (Figure 3.17). In contrast, no uptake was observed for IgG-NPs, 
and in EGFR-null H520 cells, no uptake was seen with any nanoparticles (Figure 3.17). 
 
Figure 3.17 Visualization and determination of selective binding and uptake of 225-NPs 
in NSCLC cells. HCC827 and H520 cells seeded on chamber slides were 
treated with IgG-NPs or 225-NPs (2x109 particles). Untreated cells served as 
control. At 24 hours after treatment, cells were washed, fixed, and images 
were taken under dark-field reflectance (DR) microscopy. Scale bar is 50 
µm. Selective binding and uptake of 225-NPs but not IgG-NPs was 
observed in HCC827 cells. In H520 cells, there was no binding and uptake 
of 225-NPs when compared with IgG-NPs 
A standard competition assay was also performed to determine the specificity of 
the 225-NP binding to EGFR. High pEGFR-expressing HCC827 cells were pre-treated 
with an excess of free Clone 225 antibody prior to being treated with non-specific IgG-
NPs or 225-NPs. DR images showed binding of 225-NPs was blocked by pre-treatment 
of free Clone 225 antibody (Figure 3.18) 
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Figure 3.18 225-NP is specific for EGFR-expressing tumor cells and pre-treatment with 
Clone 225 antibody abrogates 225-NP-mediated tumor cell killing. (a) The 
right column shows images of HCC827 cells pre-treated with Clone 225 
antibody (2 µg/mL) for 15 minutes before incubation with either IgG-NPs 
(middle row) or 225-NPs (bottom row). Cells shown in the left column were 
not treated with free Clone 225 antibodies. The fixed cells were imaged 
using dark-field reflectance microscopy. Binding and uptake of 225-NPs 
was completely inhibited in the presence of Clone 225 antibody. In IgG-NP-
treated cells, Clone 225 antibody had no effect. Scale bar is 50 µm. (b) 
Inhibition effect on the cytotoxicity of 225-NPs by pre-treatment with free 
Clone 225 antibody. After treatment with/without Clone 225 antibody 
(0.065 µg/mL) for 6 hours, the cells were treated with either non-conjugated 
nanoparticles (AuFe), IgG-NPs, or 225-NPs for an additional 66 hours. The 
number of viable cells was counted as described in Materials and Methods. 
Results shown are the means ± S.D. of three independent experiments. *P-
value<0.05 vs. AuFe alone, Clone 225 antibody alone, IgG-NPs, or Clone 
225 antibody plus 225-NPs. (c) Inhibition effects on 225-NP-induced 
apoptosis and autophagy by pre-treatment with Clone 225 antibody. Cellular 
proteins were lysed after treatment with 225-NPs (6x109 particles) for 66 
hours in the presence or absence of free Clone 225 antibody (0.065 µg/mL). 
Proteins were separated by SDS-PAGE, and immunoblotted with anti-PARP 
and anti-LC3 antibodies. The anti-β-actin antibody was used as a control for 
protein loading and transfer. The intensities of the amount of LC3-II bands 
were quantified by ImageJ software. 225-NP-mediated activation of 
apoptosis and autophagy as indicated by cleavage of caspase-3, PARP, and 
LC3-II respectively was markedly abrogated in the presence of free Clone 
225 antibody.  
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Pre-treatment with free Clone 225 antibodies attenuated the cytotoxicity effect of 
225-NP conjugates, leading to a reduced amount of apoptosis and autophagy observed in 
HCC827 cells compared to no pre-treatment (Figure 3.18b,c). A similar reduction in 
apoptosis and autophagy was observed for medium pEGFR-expressing H1299 cells 
treated with 225-NPs after being pre-treated with free Clone 225 antibodies (Figure 3.19). 
In conclusion, 225-NPs interacted specifically with EGFR and induced a 
molecular-specific enhanced cell death effect on EGFR-overexpressing NSCLC cells. 
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Figure 3.19 Visualization and determination of selective binding and uptake of 225-NPs 
in H1299 cells. (a) In the right column, cells were treated with free Clone 
225 antibody (2 µg/mL) for 15 minutes, and then incubated with either IgG-
NPs or 225-NPs for an additional 24 hours. The left column was not pre-
treated with free antibodies. Images were obtained using dark-field 
reflectance microscopy. Binding was inhibited by pre-treatment with free 
antibodies. In IgG-NP-treated cells, pre-treatment had no effect. Scale bar is 
50 µm. (b) Inhibition effects of free Clone 225 antibody on the cytotoxicity 
of 225-NPs. After pre-treatment with antibody (0.065 µg/mL) for 6 hrs, cells 
were treated with 225-NPs for an additional 66 hrs. Cells were treated with 
225-NPs, free Clone 225 antibodies, non-conjugated NP (AuFe), and IgG-
NPs. Results are the means ± S.D. of three independent experiments. *P-
value<0.05 vs. AuFe alone, free Clone 225 antibody, IgG-NP, or Clone 225 
antibody plus 225-NP. (c) Inhibition effects of pre-treatment with 225-NPs 
(6x109 particles) for 66 hrs in the presence or absence of free antibody. 
Proteins were separated by SDS-PAGE, and immunoblotted with anti-PARP 
and anti-LC3 antibodies. The intensities of the amount of LC3-II bands were 
quantified by ImageJ software. 225-NP-mediated activation of apoptosis and 
autophagy as indicated by cleavage of caspase-3, PARP, and LC3-II 
respectively was markedly abrogated in the presence of free Clone 225 
antibody. PARP cleavage was not detectable in all of the groups. 
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3.3.4.5 Density of antibodies attached to the surface of nanoparticles is important 
The dependence of therapeutic efficacy of nanoparticles on the density of Clone 
225 antibodies conjugated to the surface of the nanoparticles was investigated. Ratios of 
Clone 225 antibody to non-specific IgG antibody of 1:0, 1:1, 1:3, 1:10, 1:40, and 0:1 
were conjugated to the surface of the nanoparticle. A conjugate with ratio 1:0 
corresponded to the original 225-NP while a ratio of 0:1 corresponded to a nanoparticle 
conjugated to only non-specific IgG antibodies. The relative density of antibodies 
conjugated to the surface of the nanoparticles was confirmed using a fluorescent assay. 
More details of this method can be found in the Materials and Methods section Chapter 
3.2.2. The total amount of antibodies on the surface of the nanoparticle was kept constant 
between all nanoparticles. Nanoparticles of 1:0 ratio which are 225-NPs showed 
significantly higher cell killing effect (p<0.05) on high pEGFR-expressing HCC87 cells 
and medium pEGFR-expressing H1299 cells compared to nanoparticles of 0:1 ratio, 
which were non-specific IgG-NPs. As the density of the Clone 225 antibodies on the 
surface of the nanoparticle decreased, so did the cell killing effect on both cell lines 
(Figure 3.20a). The same trend was observed when autophagy was measured in these 
cells (Figure 3.20b,c). This density-dependent therapeutic effect can steer therapeutic 
strategies towards developing nanoparticles that can hold extremely high loadings of 
therapeutic antibodies216. 
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Figure 3.20 Effect of antibody density on 225-NP-mediated killing of NSCLC cells. (a) 
Cell growth inhibition in response to treatment with nanoparticles that had 
varying ratio (1:0, 1:1, 1:3, 1:10, 1:40, and 0:1) of Clone 225 antibody and 
anti-rabbit IgG antibody co-conjugated to the nanoparticle surface. Cells 
(HCC827, H1299, and H520) were treated with nanoparticles (6x109 
particles) for 72 hours. The number of viable cells was counted as described 
in Materials and Methods. Results are the means ± S.D. of three independent 
experiments. *P-value<0.05 for 225-NPs (1:0) vs. nanoparticles with 1:1 – 
1:40 and 0:1 nanoparticles on HCC827 and H1299 cells. H520 cells showed 
no inhibitory effect when treated with nanoparticles of different ratios. (b) 
The number of GFP-LC3 dots induced by 225-NPs (1:0)-treatment on 
HCC827 and H1299 cells decreased with changes in Clone 225 antibody: 
anti-rabbit IgG antibody ratio. Results are the means ± S.D. of three 
independent experiments. *P-value<0.05 for 225-NPs (1:0) vs. 1:1 – 1:40 
and 0:1 nanoparticles on HCC827 and H1299 cells. (c) 225-NPs (1:0)-
mediated reduction in the pEGFR and p44/42MAPK expression was 
abrogated in HCC827 and H1299 ells when treated with nanoparticles of 1:1 
and 1:40 ratio. 
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This observed decrease in cell killing effect can be attributed to decreasing 
density of therapeutic Clone 225 antibody on the surface of the nanoparticles, which led 
to a decrease in valency. Previous report have shown that increasing the valency of a 
molecule can increase the binding affinity of the molecule to its target196-197. For more 
details on this multivalent effect, see Chapter 3.1.2. In contrast, EGFR-null H520 cells 
showed little to no cytotoxicity when treated with nanoparticles with varying ratios of 
antibodies. 
In conclusion, nanoparticles coated completely in Clone 225 antibodies showed 
the greatest cytotoxic effect, and decreasing the density of these therapeutic antibodies 
led to a decreased antitumor effect. This study also demonstrated the specificity of 225-
NPs’ cell killing on NSCLC cells. 
3.3.5 Conclusions and Discussion 
We demonstrate that EGFR-targeted 225-NP conjugates are selectively taken up 
by EGFR-overexpressing NSCLC cells and produced an enhanced antitumor effect by 
inducing both autophagy and apoptosis. The enhanced tumor cell killing is attributed to 
the unique properties conferred by the conjugation of Clone 225 antibody with AuFe 
nanoparticles. While previous research using EGFR-targeted plasmonic gold 
nanoparticles has focused only on the ability of the gold nanoparticles to induce 
photothermal therapy, we have demonstrated another route of cell death here, via 
multivalent enhancement of a therapeutic antibody. This enhanced effect is immediately 
significant because the therapeutic molecule being studied is currently used in the clinic 
and enhancing the molecule’s effect can lead to better survival rates as well as minimize 
the dose. Additionally, this is the first study to reveal the cell death pathways that are 
activated by this 225-NP conjugate. This information helps us understand the exact effect 
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of our therapeutic molecule and can lead us to tailor designs of future nanoparticle 
conjugates for specific individual patients’ needs. 
Future work will focus on attempting to elucidate activated pathways of the 
conjugates and other effects that are different between targeted, therapeutic nanoparticles 
and controls. Another future path is to determine if combination therapy can enhance the 
effect of these conjugates because previous studies suggest this is possible217. 
Additionally, previous studies have shown that these hybrid core/shell iron oxide/gold 
nanoparticles yield strong T2 weighted contrast in MRI because of the iron oxide 
component of the nanoparticles112b. Thus, future work will involve monitoring these 
conjugates in vivo using MRI. 
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Chapter 4: Clearance of Hybrid Gold Nanoparticles 
4.1 INTRODUCTION 
In the past couple of decades, various plasmonic gold nanoparticles have been 
extensively investigated as near infrared (NIR) image contrast agents for biomedical 
applications. Absorbance of these agents in the NIR wavelength range is desired because 
this range is where the tissue optical window lies. Intravenous administration of these 
agents allows the agents to be rapidly dispersed throughout the body. Previous reports 
have indicated that nanoparticles of the size 6-100 nm exhibit sufficiently long blood 
residence time to accumulate at diseased sites such as cancer and cardiovascular 
plaques218. If particles are <6 nm, they can be removed quickly from the blood stream 
through pores between endothelial cells lining blood vessels and be filtered through the 
kidneys164. On the other extreme, particles >100 nm are quickly removed from the blood 
stream by the body’s immune cells219.  
Along with long blood circulation, an ideal nanoparticle for biomedical 
applications would also have a large optical cross-section for imaging and potential 
photothermal therapy. Nanoparticles of larger dimensions have larger optical cross-
sections. Metal nanoparticles of the size 50 nm or larger have shown strong NIR 
absorbance22, 127b, 193, 220. 
As inorganic nanoparticles are not biodegradable, there exist concerns about their 
long-term toxicity164, 221. These concerns have restricted their translation to the clinic. The 
FDA mandates that diagnostic agents must be completely cleared in a reasonable time164. 
Thus, translation of the nanoparticles to the clinic involves their ability to be efficiently 
cleared by the body. Previous studies indicate that nanoparticles must be less than 6 nm 
to be efficiently cleared164. Thus, there is a conflict between two essential optimal sizes 
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for a biomedical imaging and therapeutic agent: optimal size for delivery, imaging, and 
therapy (50 nm or greater), and optimal size for efficient clearance (<6 nm). 
Here, we address this conflict by developing a flexible platform for the kinetically 
controlled assembly of sub-5 nm gold particles to produce ~100 nm biodegradable 
nanoclusters with strong NIR absorbance for multimodal and multifunctional 
applications. The nanoclusters are stabilized with a small amount of weakly adsorbed 
biodegradable triblock co-polymer: PLA(2K)-b-PEG(10K)-b-PLA(2K). The polymer 
degrades under physiological conditions to release the constituent clearable gold 
particles. These clusters can provide sufficient blood residence time for clinical 
applications, while facilitating effective clearance from the body after biodegradation 
(Figure 4.1a). Close spacing between the gold particles within the 100 nm clusters 
facilitates strong NIR absorbance. The hydrophilic PEG loops in the center block of the 
polymer extend into the aqueous environment and provide steric stabilization for the 
clusters. The results from this chapter have been recently published in the journal ACS 
Nano222. 
4.2 MATERIALS AND METHODS 
4.2.1 Gold particle synthesis 
To synthesize the citrate-capped gold nanoparticles, 100 mL of deionized (DI) 
water was heated to 97°C. While stirring, 1 mL of 1% HAuCl4·3H2O, 1 mL of 1% 
Na3C3H5O(COO)3·2H2O, and 1 mL of 0.075% NaBH4 in a 1% Na3C3H5O(COO)3·2H2O 
solution was added in 1 minute intervals. The solution was stirred for 5 minutes and then 
removed to an ice bath to cool to room temperature. The gold particles were then 
concentrated using centrifugal devices (Ultracel YM-30, Millipore Co.) to 3 mg Au/mL. 
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Gold concentrations were determined using flame atomic absorption spectroscopy 
(FAAS), as described below. 
4.2.2 Nanocluster characterization 
The nanocluster morphology was observed by scanning electron (SEM) and 
transmission electron microscopy (TEM). A Zeiss Supra 40VP field emission SEM was 
operated at an accelerating voltage of 5-10 kV. SEM samples were prepared by 
depositing a dilute aqueous dispersion of the nanoclusters onto a silicon wafer. The 
sample was then dried and washed with DI water to remove excess polymer. TEM was 
performed on an FEI TECNAI G2 F20 X-TWIN TEM using a high-angle annular dark-
field detector. A dilute aqueous dispersion of the nanoclusters was deposited onto a 200 
mesh carbon-coated copper TEM grid for observation. Separation distances between 
primary particles within the nanoclusters were measured by analyzing TEM images using 
Scion Image software (Frederick, Maryland). UV-Vis spectra were obtained with a 
Varian Cary 5000 spectrophotometer and a 1 cm path length. Dynamic light scattering 
(DLS) measurements of hydrodynamic diameter and zeta-potential measurements were 
performed in triplicate on a Brookhaven Instruments ZetaPlus dynamic light scattering 
apparatus (scattering angle of 90°) at a temperature of 25°C. Dispersion concentrations 
were adjusted with either DI water for DLS measurements of pH = 7.4 buffer (10 mM) 
for zeta-potential measurements to yield a measured count rate between 300 and 400 
kcps. Prior to all DLS measurements, the nanocluster dispersions were filtered through a 
0.2 µm filter and probe sonicated for 2 minutes. Data analysis was performed using a 
digital autocorrelator (Brookhaven BI-9000AT) with a non-negative least-squares 
(NNLS) method (Brookhaven 9KDLSW32). Reported average diameters correspond to 
the D50 or diameter at which the cumulative sample volume was under 50%. For zeta-
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potential measurements, the average value of at least three data points was reported. 
Thermogravimetric analysis (TGA) was conducted using a Perkin-Elmer TGA 7 under 
nitrogen atmosphere at a gas flow rate of 20 mL/min. The samples were cleaned to 
remove excess polymer by centrifuging nanocluster dispersions at 800°C for 30 minutes. 
Flame atomic absorption spectroscopy (FAAS) was used to determine the gold 
concentration in the nanocluster dispersion using a GBC 908AA Flame atomic absorption 
spectrometer (GBC Scientific Equipment Pty Ltd.). Measurements were conducted at 
242.8 nm using an air-acetylene flame. To determine clustering efficiency, dispersions of 
nanoclusters of known concentration were centrifuged at 10,000 rpm for 10 minutes at 
4°C. FAAS measurements were conducted on the supernatant. 
4.2.3 Hyperspectral characterization of nanoclusters in solution 
Microscope slides were submerged in a warm, aqueous gelatin solution (3% w/v) 
for 10 minutes. The slides were removed from the gelatin and 10 µL of a dilute 
nanocluster dispersion (~0.01 mg/mL) was placed on the gelatin-coated slide and covered 
with a coverslip. The gelatin was allowed to cool for 2 hours to allow the nanoparticles to 
solidify into the gelatin. Hyperspectral images were acquired under the same conditions 
as described below for cell studies. 
4.2.4 Cellular studies of nanocluster disassembly 
The cells were J774A.1 murine macrophage cells (American Type Culture 
Collection, Manassas, VA) and were cultured in a 12-well plate in a phenol-free DMEM 
media (Gibco, Grand Island, NY) supplemented with 5% fetal bovine serum (Hyclone, 
Logan, UT) and antibiotics (Gibco, Grand Island NY) and incubated at 37°C in a 5% CO2 
environment for 1 week. The nanoclusters were filtered through a 0.45 µm filter 
(Corning, Corning, NY) spun down and resuspended in DMEM medium and, then, were 
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added to each well with cells (0.4 mg per well). Incubation of the cells with the 
nanoclusters occurred over 24 hours, after which the excess of the nanoparticles was 
removed and the cells were allowed to proliferate to 96 or 168 hour time points. The cells 
were washed three times in 0.01 M phosphate buffered saline (PBS), harvested, and 
centrifuged at 110 x g for 3 minutes. The supernatant was discarded. The cells were 
resuspended in 10 µL of PBS, placed on a microscope slide, and imaged using a 
combination of dark-field reflectance (DR) and hyperspectral (HS) imaging. DR 
microscopy images of the cells and nanoclusters were taken with a Leica DM6000 
upright microscope, and the hyperspectral system was calibrated using a standard 
wavelength calibration lamp (low pressure Hg, Lightform, Inc.). All HS spectra from 
cells were normalized by the spectrum of the Xe excitation light source on a pixel by 
pixel basis. RGB images were taken with a Q-imaging Retiga EXi CCD camera with 
color LCD attachment. Images were white balanced with a Spectralon (Labsphere, North 
Sutton, NH), and the acquisition settings were chosen such that all samples were acquired 
under identical conditions. 
For the studies involving TEM of cells, approximately 3x104 cells were seeded 
overnight on Aclar Embedding Film (Electron Microscopy Sciences, Hatfield, PA). All 
samples for TEM imaging were treated identically and were run in parallel to the samples 
used for optical imaging. At each time point, the cells were fixed in a 1% glutaraldehyde 
and 1% paraformaldehyde solution for 1 hour at room temperature and then washed three 
times in PBS. Subsequently, cells were stained with 2% osmium tetroxide in water for 10 
minutes and washed for 10 minutes in water. The sample was then dehydrated using 
increasing ratios of ethanol to acetone solutions and finally embedded in an epoxy-
acetone mixture and allowed to bake at 60°C for 24 hours. Ultrathin sections were sliced 
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using a Leica Ultracut microtome (Leica, Deerfield, IL) and imaged with a Tecnai G2 
TEM at a voltage of 80 kV. 
4.2.5 Mice studies 
Female 2-4 months old Balb/c mice (Jackson Labs) were used for all mice studies. 
All procedures performed on the mice were approved by the University’s Institutional 
Animal Care and Use Committee. Mice were divided into three groups: non-degrading 
solid nanoparticle-injected, biodegradable nanocluster-injected, and PBS-injected mice. 
Each nanoparticle-injected group contained 4 mice, while the PBS-injected group 
contained 3 mice. Mice were followed up to 4 months, with time points of sacrifice 1 
day, 1 week, 1 month, 2 months, 3 months, and 4 months. At each time point, organs 
were harvested and analyzed using inductively coupled plasma mass spectrometry (ICP-
MS) and microscopy. Mice were placed individually in metabolic cages to collect urine 
and feces samples from each mouse for analysis of cleared nanoparticles. PBS-injected 
mice were only followed up to 1 month because of a limited number of cages. 
Mice were given a 200 µL injection of either nanoparticles (6 mg/mL) or PBS via 
tail vein. 
4.2.6 Inductively coupled plasma mass spectrometry 
Harvested organs from mice were digested using a microwave digestion system 
(MARS Xpress, CEM GmbH, Germany). Samples were digested using a mixture of 35% 
HNO3 (Fisher Scientific) and 18.5% HCl (Fisher Scientific) in the microwave to 
homogenize, and samples were analyzed using inductively coupled plasma mass 
spectrometry (ICP-MS). Samples were then diluted to <10% acid in water and calibration 
standards were prepared using a NIST gold standard of 1000 ppm Au, diluted to a range 
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of 1-50 ppb. Samples were then analyzed using an ICP-MS (GBC Scientific Equipment, 
Australia). 
4.3 RESULTS 
4.3.1 Current methods of synthesizing assemblies of nanoparticles 
Properties of assemblies of nanoparticles such as size and interparticle spacing are 
controlled by varying particle volume fractions during solvent evaporation. The changes 
in electrostatic, van der Waals (VDW), depletion, and steric interactions on the 
concentration of the gold nanoparticles and polymer micelles govern the kinetic assembly 
of the nanoclusters as well as their disassembly after polymer degradation223. Without the 
presence of a polymeric stabilizer, irregular micrometer-sized aggregates of gold 
nanoparticles have been formed by varying the particle charge after adjusting the pH for 
particles capped with lysine221, 224, cysteine225, or glutathione226 ligands. Alternatively, 
nanoclusters composed of metal particles may be formed by equilibrium self-assembly 
with polymer templates227 but the high polymer concentrations required for the 
equilibrium assembly typically lead to metal loadings and interparticle spacings that are 
not sufficient for strong NIR absorbance. Additionally, the templating agents are highly 
specialized. 
In contrast, our kinetically controlled assembly platform requires only small 
concentrations of commonly used copolymers as stabilizers and simple biocompatible 
capping ligands on gold, such as citrate and/or lysine. 
4.3.2 Nanocluster characterization 
4.3.2.1 Morphology 
Nanocluster growth is controlled by mediation of the interactions between ligand-
capped gold particles with biodegradable polymer (Figure 4.1b).  
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Figure 4.1 Schematic of synthesis and degradation of gold nanoclusters. (a) Illustration 
of a biodegradable nanocluster, which is composed of ~4 nm primary gold 
particles held together with a biodegradable polymer. Upon polymer 
degradation, catalyzed by low pH in endosomal compartments of cells, the 
nanocluster deaggregates into primary gold nanoparticles. (b)Schematic of 
nanocluster formation process, in which primary gold nanoparticles 
aggregate in the presence of a polymer in a controlled manner to yield sub-
100 nm clusters. Polymer adsorption to the nanoparticle surface and an 
increase in the volume fraction of particles, Φ, via solvent evaporation 
promote cluster formation. 
Gold nanoparticles stabilized with citrate ligands were synthesized based on a 
previously published method228. Lysine was used as a stabilizing agent for the gold 
nanoparticles, and led to an average diameter of 4.1±0.8 nm (Figure 4.2a and Figure 4.3).  
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Figure 4.2 Electron microscopy characterization of gold nanoclusters. (a) TEM of 
initial 4 nm lysine/citrate-capped gold nanoparticles before clustering. (b) 
SEM and (c) TEM micrographs of nanoclusters template using PLA(2K)-
PEG(10K)-PLA(2K) at a 16/1 polymer/Au ratio (w/w). For TEM 
micrographs, the stage was tilted at an angle of -40, 0 (no tilt), and 40°. 
These lysine-capped gold spheres were mixed with the polymer PLA(2K)-
PEG(10K)-PLA(2K) yielding a final polymer concentration of 50 mg/mL. The dispersion 
was sonicated in a water bath for 5 minutes and the dispersion changed from ruby red in 
color to a darker red-purple color. Upon evaporation of ~80% of the solvent, the 
dispersion turned blue, indicating absorption in the red wavelength region. Complete 
solvent evaporation over 2 hours produced a smooth blue film, and reconstitution of the 
film in deionized (DI) water to a concentration of 0.3 mg/mL yielded a dark blue 
dispersion.  
 
 97
 
Figure 4.3 Summary of absorbance maximum and size of nanoclusters (measured by 
DLS) and primary particles  (measured by TEM) for lysine/citrate and 
citrate only capped primary gold particles.  aAbsorbance measurement were 
recorded at gold concentrations of ~56 µg/mL. All nanoclusters were 
formed using the polymer PLA(2K)-b-PEG(10K)-b-PLA(2K). 
SEM was used to determine the nanocluster size of ~ sub-100 nm. A highly 
scattering core can be seen within a lighter scattering shell indicating the hydrophilic 
PEG polymer surrounds the assembly of gold nanoparticles in the center of the cluster. 
This polymer sterically stabilizes the clusters in solution. Additionally, 
thermogravimetric analysis (TGA) indicated that the nanoclusters contained only 20±5% 
organic material (polymer and ligands), where 10-15% consisted of polymer. TEM 
images taken at various angles revealed closely-spaced primary gold nanoparticles 
throughout the porous cluster. DLS revealed the hydrodynamic diameter to be 83±4.6 
nm, which is in agreement with TEM results (Figure 4.3 and Figure 4.4a). 
 
 98
 
Figure 4.4 Degradation of gold nanoclusters in solution. (a) Hydrodynamic diameter 
(DLS) in pH 7.4 media initially and after 168 hrs (1 week) of incubation. (b) 
UV-Vis-NIR absorbance spectra of (1) colloidal dispersion of lysine/citrate-
capped gold nanoparticles, (2) biodegradable nanoclusters (pH = 7.4), and 
(3) deaggregated nanoclusters (pH = 5). (c) Size distribution after 
deaggregation in pH = 5 media, as determined by image analysis of TEM 
micrographs (>200 particles). Inset: TEM micrograph of nanoclusters after 
incubation at pH = 5 for 1 week. 
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These low polymer loadings allow for close spacing of the primary gold particles. 
These low loadings are facilitated by control of the depletion forces and the propensity of 
the PEG blocks to migrate towards the water interface and thus be present mostly on the 
surface of the cluster. Interparticle distances between the primary particles were 
estimated to be 1.8±0.6 nm from TEM images (Figure 4.5). 
 
 
Figure 4.5 Histogram of separation distances between primary gold nanoparticles 
within a nanocluster. Measurements were taken using particles on the 
periphery of the nanoclusters. Inset is a TEM image of one of the clusters 
that was used in this measurement. >130 data points were taken. 
This spacing is consistent with the length of a lysine-lysine dipeptide in solution, 
which is 1.49 nm229. The ability to control both cluster size and interparticle spacing was 
achieved by manipulating the particle volume fractions upon solvent evaporation, and 
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controlling the electrostatic, van der Waals, depletion, and steric interactions between the 
gold primary particles and the polymer. This approach provides a large amount of control 
over nanocluster morphology compared to nanoclusters formed by reducing gold 
precursors without a polymer stabilizer230. 
4.3.2.2 Optical properties 
Optical extinction spectra changed markedly between primary gold spheres and 
nanoclusters (Figure 4.4b) An initial dispersion of gold nanoparticles had a maximum 
absorbance at 520 nm, which is characteristic of isolated gold spheres, but upon cluster 
formation, the absorbance red-shifted and broadened into the NIR region, with a broad 
maximum spanning 700-900 nm. The extinction cross-section was calculated to be ~10-14 
m2, which is comparable to NIR absorbing gold nanoparticles commonly used in 
biomedical research such as rods56, cages220c, and nanoshells127b. 
Extinction cross-section was calculated using Beer-Lambert’s Law as given in 
Equation (4): 
 
ܣ ൌ ߝሺߣሻܥߡ  (4) 
Where A is absorbance, ε is the wavelength-dependent extinction coefficient, C is 
concentration, and ι is the path length. For a path length of 1 cm and a concentration of 
gold of 56 µg/mL, a maximum absorbance of 1.1 was found at a wavelength of 703 nm. 
Using Beer-Lambert’s Law, the extinction coefficient at 703 nm was 0.02 cm2/µg. 
Assuming that the nanoclusters are spherical and have a diameter of 100 nm, in a closest-
packed state, the extinction cross-section (product of extinction coefficient and mass of 
gold per nanocluster) is ~1x10-14 m2.  
 101
The high NIR absorbance observed for nanoclusters can be attributed to multiple 
factors: close interparticle spacing between primary particles, non-uniform spatial 
distribution of primary particles, roughness of surface, and a deviation from a spherical 
shape. TEM images (Figure 4.2)) show that short oligomers of primary particles and 
subcluster domains can be clearly observed, indicating a non-uniform volume-packing 
distribution, which has been known to enhance the red-shift of the surface plasmon 
resonance76, 231. The NIR absorbance of the nanoclusters per total particle mass is much 
higher than previous composite particles with smaller amounts of gold nanoparticles 
synthesized via templates with liposomes, block copolymer micelles, or DNA227b, c, 232. 
We also demonstrated the assembly of primary gold spheres into nanoclusters with strong 
NIR absorbance with citrate-capped gold nanoparticles, which possess a zeta-potential of 
-44±4.9 mV, compared to -30.1±2.4 mV for the lysine/citrate-capped nanoparticles 
(Figure 4.3). The remainder of this chapter will focus on lysine/citrate-capped 
nanoclusters because of their smaller size. 
4.3.2.3 Stability and degradation in solution 
The stability and degradation of nanoclusters were examined at physiologically 
relevant pHs of 7.4 (normal cell environment) and 5 (endosomal environment233). After 
storing a solution of nanoclusters for 1 week in pH 7.4 buffer, the DLS peak shifted 
modestly toward smaller sizes (Figure 4.4a). This limited degradation is consistent with 
the long half-life of PLA(MW 2K) of about 4 weeks at neutral pH. In contrast, after 
nanoclusters were incubated in a pH of 5 (a medium of 0.1N HCl) for 1 week, near 
complete degradation of the nanoclusters was observed by TEM (Figure 4.4c and Figure 
4.3). The mean particle size of degraded clusters was 4.3±0.1 nm (n>100 particles), 
which was comparable to the initial particle size of 4.1±0.8 nm (Figure 4.6). 
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Figure 4.6 Particle size distribution of primary lysine/citrate-capped gold particles (red 
curve), nanoclusters deaggregated at pH=5 (green curve), and nanoclusters 
after biodegradation in live cells (orange curve) determined by image 
analysis of over 100 particles per sample in TEM micrographs. 
Upon degradation of the polymer, a combination of steric repulsion because of 
capping ligands and remaining polymer fragments, electrostatic repulsion because of 
negative charge of gold nanoparticles, and effective entropic forces are sufficient to 
completely redisperse the primary gold particles. The extinction spectrum of the colloidal 
gold spheres blue-shifts towards the spectrum of primary particles and the color of the 
solution changes back towards red (Figure 4.4b). The remaining discrepancy between 
these spectra is attributed to the presence of a small number of clusters (~7%) still present 
in the degraded solution. More recent work, however, has shown that smaller 20 and 30 
nm clusters have eliminated this secondary population of larger non-degrading particles. 
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Degradation of nanoclusters consisting of citrate-capped primary particles was also 
achieved. 
4.3.2.4 Degradation in cells 
Nanocluster biodegradation was then demonstrated in macrophage cells, a 
common model cell type for any clearance organ. Scattering spectra and hyperspectral 
(HS) images (Figure 4.7a,c), dark-field reflectance (DR) images (Figure 4.7b,d top row), 
and HS images (Figure 4.7b,d bottom row) were acquired at 24, 96, and 168 hrs after 
cells were treated with nanoclusters. 
High nanocluster uptake was observed in the DR images, where nanoclusters 
strongly scattered the illuminated light. Overall scattering intensity decreased over time 
as macrophages divided and nanoclusters were distributed between daughter cells (Figure 
4.7b, top row). A significant increase in red-NIR scattering signal of the labeled cells was 
seen compared to unlabeled cells (compared Figure 4.7a, dark blue curve and c), 
consistent with the high scattering of clusters in solution (Figure 4.7a, light blue curve).  
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Figure 4.7 Biodegradation of gold nanoclusters inside live cells. Scattering spectra 
(normalized by area under the curve) of (a) live cells labeled with 
nanoclusters and (c) control cells without nanoclusters. The spectra were 
taken at 24, 96, and 168 hrs after cells were treated with nanoclusters. Dark-
field reflectance (DR) images of cells treated with (b) nanoclusters and (d) 
control cells over time are shown together with corresponding color coded 
images indicating scattering peak position at each pixel in the field of view 
(b and d, bottom rows). Hyperspectral (HS) images and the color bar were 
used to obtain the color coded distribution of scattering peaks within cells (b 
and d, bottom row). Pixels that did not have an identifiable peak in a 
corresponding spectrum were not assigned a color. The scale bar in the DR 
and HS images is 10 µm. (e) TEM images of cells treated with nanoclusters 
at low magnification (scale bar 2 µm) and high magnification (scale bar 100 
nm) at 24 and 168 hrs. Red boxes in the low magnification images are 
magnified on the right at each time point. 
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The relative intensity of the red-NIR scattering signal decreased after 96 hrs, and 
the scattering from labeled cells showed a marked blue shift to 550 nm, which is 
consistent with scattering from constituent lysine-citrate-capped gold nanoparticles 
(Figure 4.8). 
 
 
Figure 4.8 Hyperspectral scattering spectra (normalized to the area under the curve) of 
biodegradable nanoclusters at pH=7.4 (dark-blue curve), deaggregated 
nanoclusters at pH=5 (green curve), and the primary lysine/citrate-capped 
colloidal gold (red curve). 
Hyperspectral images showed a gradual progression from very strong scattering in 
the 650-700 nm region at t=24 hrs to a less intense scattering signal predominantly in the 
500-550 nm region at t=168 hrs (Figure 4.7b, bottom row). The endogenous scattering 
from control untreated cells did not significantly change over time (Figure 4.7c,d). Note 
that the scattering from the control cells is approximately 6 times weaker than scattering 
from labeled cells. Additionally, most of the pixels in the HS image of untreated cells do 
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not exhibit any distinct scattering peaks, which result in a black appearance in the images 
in Figure 4.7d, bottom row. The biodegradation of nanoclusters inside live cells was 
further confirmed by TEM (Figure 4.7e). After 24 hrs, large ~100 nm clusters can be 
observed throughout the interior of cells (Figure 4.7e, 24 hrs), whereas after 168 hrs, cells 
contain only particles less than 5 nm (Figure 4.7e, 168 hrs). These TEM results are in 
excellent agreement with the optical measurements and with results in solution, providing 
unambiguous proof that the nanoclusters are achieving complete biodegradation of the 
initial 100 nm nanoclusters into sub-5 nm primary particles (Figure 4.6). 
4.4 Animal studies 
The in vivo behavior of nanoclusters was investigated in normal Balb/c mice. 
Mice were injected via tail vein with 200 µL of 6 mg/mL of either 40 nm biodegradable 
gold nanoclusters or 10kD PEGylated 40 nm non-degrading gold particles in phenol-free 
DMEM media. Mice injected with PBS were used as a control. Tissues were harvested 
for inductively coupled plasma mass spectrometry (ICP-MS) analysis at time points: 1 
day, 1 week (7 days), 1 month (28 days), 2 months (56 days), 3 months (84 days),and 4 
months (112 days) after injection. 
Biodistribution results revealed that both biodegradable nanoclusters and non-
degrading solid spheres accumulated significantly (~70% injected dose) in clearance 
organs: liver, spleen, and kidney by the initial time point of 1 day, as expected (Figure 
4.9). Control PBS-injected mice did not yield any gold in these organs. Over time, both 
non-degrading solid spheres and biodegradable nanoclusters cleared from these clearance 
organs at a similar rate until the final time point of 4 months (112 days), where the 
concentration of nanoclusters dropped markedly compared to non-degrading spheres. 
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These results indicate that even though initial clearance is fairly slow, the nanoclusters 
will clear the body faster than non-degrading particles.   
 
 
 
Figure 4.9 % Injected dose (ID) of gold found in clearance organs: liver, spleen, and 
kidneys, combined, over time. Both clusters (blue curve) and solids (red 
curve) showed a drop in gold content in clearance organs over time. 
Clusters, however, exhibited a larger drop than solids at the final time point 
of 112 days  (4 months). PBS-injected mice were used as a negative control 
and did not show gold content in clearance organs. Control mice were only 
analyzed up to a third time point (1 month after injection). 
While the accumulation of the biodegradable nanoclusters and the non-degrading 
spheres was very similar in all of the clearance organs (liver, spleen, and kidneys) 
combined over time, the distribution between individual clearance organs was 
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significantly different for the two particle types even at initial time points (Figure 4.10). 
Nanoclusters initially accumulated mostly in the liver (~70% injected dose (ID)) with 
very little accumulation in the spleen (2% ID) or kidneys (0.2% ID). In contrast, non-
degrading spheres distributed more evenly between the clearance organs, with ~40% ID 
found in the liver after 1 day, 24% ID in the spleen, and 3% ID found in the kidneys 
(Figure 4.10). This significant difference in distribution between nanoclusters and non-
degrading spheres has been observed with other types of particles. Perry and colleagues 
showed that non-PEGylated nanoparticles accumulated mostly in the liver, while 
PEGylated nanoparticles accumulated more evenly between both liver and spleen96. The 
hypothesis for this difference was that PEGylated particles, which can circulate longer 
than non-PEGylated particles, have more time to interact with the spleen, while particles 
with shorter circulation time interact initially with liver96. This effect can be explored for 
future studies with the aim of avoiding both clearance organs. 
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Figure 4.10 %Injected dose (ID) of gold from biodegradable 40 nm clusters (blue 
curves), solid non-degrading 40nm (red curves), and control PBS (green 
curves) injected in mice. Organs analyzed over time were: liver (top), spleen 
(middle), and kidney s (bottom). A significant drop in gold was observed in 
the liver of mice injected with nanoclusters after 4 months compared to 
initial time points 1, 7, and 30 days after injection  (blue curve, top graph) 
(*p<0.05). No other curves showed a significant change over time. Clusters 
accumulated mostly in the liver, while solids were more evenly distributed 
between the liver, spleen, and kidneys. 
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Nanoclusters in the liver showed a significant decrease (p<0.05) after 4 months, 
while non-degrading spheres did not exhibit any significant change over time. Moreover, 
neither particles in the spleen nor kidneys showed any change over time. The significant 
drop in concentration of clusters from the liver compared to non-degrading particles is 
promising for more optimized clusters to clear at an even faster rate from the body. For 
future studies, to increase rate of clearance of nanoclusters in vivo, smaller 20nm 
nanoclusters will be explored234. These nanoclusters show no opsonization in serum for 
both intact and degraded nanoclusters235 and show promise to clear at a fast rate from the 
body than the previously studies 40 nm nanoclusters. 
4.5 CONCLUSIONS AND DISCUSSION 
We have developed a general kinetic assembly platform for the design of hybrid 
polymer/gold nanoclusters smaller than 100 nm with closely-spaced gold spheres that 
produce strong absorbance in the NIR. Only small amounts of biodegradable polymers 
are needed to reduce electrostatic repulsion between gold particles to stabilize the 
clusters. These nanoclusters have both high optical cross-sections required for imaging 
and therapy, prolonged blood residence time required for effective targeting to a diseased 
site, and ability to be degraded into efficiently clearable components which is required for 
minimizing exposure of the agent to the body in the long-term, thus minimizing potential 
toxic effects. This method of assembling primary gold particles can serve as a platform 
for tuning parameters such as varying surface chemistries, which play a large role in 
clearance, or synthesizing an assembly comprised of multiple types of materials to allow 
for multimodal imaging and multifunctional applications such as targeting and therapy. 
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The combination of all these tunable parameters can be explored to facilitate translating 
plasmonic nanoparticles to the clinic.  
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Chapter 5: Conclusions and Future Work 
5.1 CONCLUSIONS 
Chapter 2 described properties of gold nanoparticles that make this nanoparticle 
an attractive sensing, imaging, and therapeutic agent. Gold nanoparticles have 
consistently shown strong optical imaging capabilities because of high optical cross-
sections compared to conventional clinically used imaging agents: fluorophores and 
organic dyes. Also, these nanoparticles can be of the size to allow for fairly long blood 
residence time and thus have served as delivery vehicles for targeting agents and drugs. 
One area of concern, however, is the fact that even though there is an abundance of 
research in developing stealthy and targeted nanoparticles, many nanoparticles are still 
cleared from the bloodstream by the MPS. This fact is further complicated by the fact that 
inorganic nanoparticles such as gold do not degrade and thus can have a potential of 
causing long-term negative side effects in vital organs.  
Chapter 3 demonstrated that by conjugating a therapeutic antibody to the surface 
of a nanoparticle, the therapeutic efficacy of the therapeutic molecule was increased 
compared to free antibody, via a multivalent effect, which has been demonstrate 
numerous times to enhance binding affinity of molecules. Additionally, cell death 
pathways that were activated by this therapeutic conjugate were shown to be a 
combination of the known programmed cell death pathways: autophagy and apoptosis, 
giving us a better understanding of how our treatment is working. These pathways were 
not activated using individual components of the conjugate, showing that the assembly of 
the conjugates provides a unique therapeutic enhancement to components that have been 
studied more extensively on their own. This conjugate was also comprised of multiple 
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materials to allow for multimodal imaging, which many think will be the next area of 
major advancement towards personalized medicine. 
Chapter 4 provided a method of developing plasmonic particles that were both 
large enough to have strong optical cross sections and as long of a circulation time that a 
particle of this size can have, and over time, small enough to be of the size that is renally 
and efficiently clearable. We showed that these particles degrade in cells to primary 
components within a week, and even showed degradation within mice, but over a much 
longer time frame, over the course of many months. These results showed that these 
particles have potential to be efficiently cleared. Additionally, these particles have strong 
NIR absorbance for high resolution, NIR imaging in vivo and are composed of multiple 
primary components, lending itself to have multifunctional and multimodal capabilities.  
5.2 FUTURE WORK 
5.2.1 Therapeutic efficacy 
Therapeutic molecules like therapeutic antibodies conjugated to plasmonic 
particles have the unique opportunity to convey a high degree of functionality in a small 
system. Future work for these conjugates involves determining therapeutic efficacy of the 
conjugates in vivo. Therapeutic efficacy of the therapeutic molecules alone has been 
demonstrated by other groups to be highly effective at inhibiting tumor growth at certain 
concentrations, and these plasmonic hybrid conjugates provide a way to not only monitor 
these therapeutic molecules in vivo but also to enhance the therapeutic effect of these 
therapeutic molecules. A major challenge to delivering a large load of drugs or imaging 
agents to a diseased site in the body is the immune system of the body. Thus, optimizing 
particle size, charge, and composition will be essential to using these particles in vivo. 
Additionally, determining cell signaling paths and molecules that are activated by these 
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conjugates will lead to the development of the conjugates as a platform to be translated to 
an individual patient’s needs. 
5.2.2 Clearance of nanoparticles 
The clearance of degradable plasmonic nanoclusters will rely on fully 
characterizing the nanoparticles’ interactions with the body’s host blood and immune 
system. Previous reports have indicated the range of sizes and charges of inorganic 
nanoparticles that can be efficiently cleared, but combining these traits with other 
essential traits like high absorbance cross sections for imaging and being initially of the 
size to allow for prolonged blood circulation complicates the scenario and requires a new 
set of characterizations.  
Overall, plasmonic nanoparticles provide a strong multifunctional platform for 
imaging and treating diseases like cancer, but before they can be translated to the clinic, 
their interactions with the body’s defense system must be fully characterized which can 
help in developing particles with increased stability and stealth. This, then, can greatly 
affect other important properties biomedical nanoparticles strive to have, such as 
increased targeting and clearance over time.  
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